Scientific Program


Scientific Program


Monday, October 6


1. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-12.00 – Monday, October 6

Chair Persons: S. Smith, M.R.J. Kohonen-Corish

  • Senescence linked inflammation, replication stress, fragile sites and DNA methylation changes in sporadic breast and prostate cancer. S. Smith (Duarte, CA, USA) (20’)
  • Identification of a new molecular pathway for beta-catenin regulation in colon cancer cells. L. Pangon, D. N. Mladenova, N. Currey, P. Lecine, J.P. Borg, M.R.J. Kohonen-Corish (Sydney, Australia; Marseille, France) (15’)
  • Stimulation of fatty acid synthesis by thyroid hormone response protein/spot14 enhances tumor cell proliferation in vivo. E.A. Wellberg, M.C. Rudolph, A. Lewis, S.M. Anderson (Aurora, CO, USA) (30’)
  • Tryptophan metabolism, neopterin and cancer. J.M. Gostner, K. Becker, F. Ueberall, D. Fuchs (Innsbruck, Austria) (30’)
  • Roles for vickz proteins in cell migration, cancer progression, and metastasis. Y. Maizels, Y.B.-Z. Rosenfeld, F. Oberman, Z. Fridlender, J. K. Yisraeli (Jerusalem, Israel) (30’)
  • Role of acetylcholine as a growth factor: focus on urinary bladder. N. Arrighi, D. Zani, M.C. Michel, S. Sigala (Brescia, Italy; Mainz, Germany) (30’)
  • Protein folding and cancer. J. Anastassopoulou, M. Kyriakidou, S. Kyriazis, V. Dritsa, T. Kormas ( Athens, Greece) (20’)
  • In-silico identification of novel bacterial antigenic proteins as potential vaccine targets against gastric cancer using reverse vaccinology approaches. A. Naz, F.M. Awan, A. Obaid, A. Ali (Islamabad, Pakistan) (15’)

1P. MOLECULAR AND CELLULAR BIOLOGY OF CANCER (POSTERS)

  • Dihydrofolate reductase protein stabilization by methotrexate is associated with upregulation of inducible nitric oxide synthase (iNOS) expression in human colon cancer cells. M. Dabrowska, Z. Zielinski, K. Litewiak, A. Jagielski, W. Rode (Warsow, Poland)
  • Spectrum of KRAS and BRAF mutations in Polish colorectal cancer patients. J. Gil, P. Palowski, P.Karpinski, M.Bebenek,M.M Sasiadek (Wroclaw, Poland)
  • Protein tyrosine phosphatases in sporadic colorectal cancer. I. Laczmanska , P. Karpinski, J. Kozlowska, E. Szmida, M. Bebenek, D. Ramsey, P. Ziolkowski, M.M. Sasiadek (Wroclaw, Poland)
  • PTEN inactivation and alteration of the PI3K/AKT/MTOR pathway in biliary tract cancer. J. Petzold, E. Lederer, R. Reihs, C. Ernst, K. Bettermann, I. Halbwedl, S. Lax, Y.N. Park, K.S. Kim, T. Kiesslich, M. Pichler, P. Obrist, J. Haybaeck (Graz; Salzburg; Zams, Austria; Seoul, South Korea; Houston, TX, USA)
  • The influence of HER2 codon 655 SNP and C-ERB-2 protein expression in P53 positive gastric cancer patients. J. Ananiev, E. Aleksandrova, K. Ivanova, E. Onal, V. Velev, ,M. Gulubova (Stara Zagora, Bulgaria)

2. ONCOGENES; TUMOR SUPPRESSOR GENES; GROWTH FACTORS; SIGNAL TRANSDUCTION

ROOM A, 13.00-16.15 – Monday, October 6

Chair Persons: D.W. Felsher, A. Seth

  • Modeling and predicting consequences of therapeutic oncogene inactivation. D.W. Felsher (Stanford, CA, USA) (40’)
  • Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. R.P. Charles, J. Silva, G. Iezza, W.A. Phillips, M. McMahon (San Francisco, CA, USA; Melbourne, Australia; Bern, Switzerland) (30’)
  • Post-translational regulation of COX2 activity by FYN in prostate cancer cells. A. Sorokin (Milwaukee, WI, USA) (25’)
  • Tumor suppressor protein IGFBP7 blocks phosphatidylinositol-3-kinase-AKT signaling by binding to the IGF-1 receptor. Y. Amemiya, T. Benatar, V. Evdokimova, W. Yang, A. Seth (Toronto,ON, Canada) (15’)
  • Steroid receptor co-activators and oestrogen receptor beta-1 isoform as survival biomarkers in malignant pleural mesothelioma. C.J. Jennings, B. Murer, A. O’Grady, B.J. Harvey, E.W. Kay, W. Thomas (Dublin, Ireland; Mestre, Italy) (30’)
  • From bench to bed, from single gene to multiplex analysis, and challenges and accomplishments in fighting lung cancer. S. Long, G. Otterson, D. Carbone, M. Villalona, Y.Tang, K. Shilo, W. Zhao (Columbus, OH, USA) (15’)
  • Right-sided tumours and related unexplained iron-deficiency anaemia(IDA) are associated with BRAF V600E mutation in colorectal cancer patients. M. Sideris, K. Adams, J. Moorhead, S. Diaz-Cano, S. Papagrigoriadis (London, UK) (10’)

2P. ONCOGENES; TUMOR SUPPRESSOR GENES; GROWTH FACTORS; SIGNAL TRANSDUCTION (POSTERS)

  • CGP1 mediated inflammasome activation and metastasis in OSCC. C.S. Wu, Y.S. Chang (Taoyuan, Taiwan, ROC)
  • Coincident expression of melanotransferrin and transferrin receptor 1 and their modulation on human melanoma cells: Mannose-6-phosphate up-regulates MTF and hyaluronan up-regulates TFR1. F. Laube (Halle, Germany)
  • CD44 expressing human melanoma cells up-regulate transferrin receptor 1 upon exposure to hyaluronan. F. Laube (Halle, Germany)
  • Introduction of EGFRvIII in MDA-MB-468 cell line results in cellsphenotype changes towardsmesenchymal one. M. Ksiazkiewicz, J. Peciak, M. Banaszczyk, E. Stoczynska-Fidelus, S. Piaskowski, M. Walczak, P. Rieske (Lodz, Poland)
  • EGFRvIIIactivates a distinct pathwaythanwild-type EGFR, but the final decisionbelongs to wild-type EGFR. C. Treda, E. Stoczynska-Fidelus, S. Piaskowski, D. Grzela, J. Zieba, M. Walczak, M. Banaszczyk, J. Peciak, P. Rieske (Lodz, Poland)

3. EPIGENETICS

ROOM A, 16.30-19.00 – Monday, October 6

Chair Persons: W. Engström, G. Broich

  • Mitotic bookmarking of genes- a novel dimension of epigenetic memory in cancer. S.Sengupta, L. Bellot, S. Nath, K.K. Bhakat (Omaha, NE USA) (40’)
  • Epigenetic regulation of the igf2/h19 locus. W. Engström, M. Nordin, D. Bergman, M. Halje, C. Laestander, E. Andersson, M.A. Lindgren, I. Lindstedt (Uppsala, Sweden) (30’)
  • Epigenetic and DNA-conformation mediated regulation of gene expression in breast cancer. A. Ray, B.K. Ray (Columbia, MO, USA) (30’)
  • Epigenetic regulations and the Vitamin D system. E. Kallay (Vienna, Austria) (20’)

4. NEW ANTICANCER AGENTS

ROOM B, 08.00-10.00 – Monday, October 6

Chair Persons: L. Amaral, S. Shany

  • Family of peptides synthesized in the human body have anticancer effects. D.L. Vesely (Tampa, FL, USA) (40′)
  • Cancer therapy with radionuclides from the natural radioactive series. R.H. Larsen, Ø.S. Bruland (Oslo, Norway) (30′)
  • Mechanism-based sirtuin inhibition. W. Zheng (Zhenjiang, Jiangsu, PR China) (40′)

5. NEW ANTICANCER AGENTS

ROOM B, 10.00-12.00 Monday, October 6

Chair Persons: H. Maeda, D.L. Vesely

  • TCP-1 as a novel phage-display peptide targeting colon cancer. C.H. Cho, L. Lu (Shatin, Hong Kong) (20′)
  • Inhibition of vitamin D degradation enhances its activity against human lung cancer cell growth. S. Shany, V. Gavrilov (Beer Sheva, Israel) (30′)
  • L-asparaginases as therapeutic enzymes for the treatment of leukemia. C.S. Karamitros, M. Konrad (Goettingen, Germany) (20′)
  • Gossypol analogs and Bcl-2 protein – Natural compounds and natural target. V. Gandhi (Houston, TX, USA) (20′)
  • Cytotoxic effect of gentisic acid and protocatechuic acid triphenylphosphonium derivatives in human breast cancer cells: Possible mechanism and bioenergetic implications. C. Sandoval-Acuña, S. Fuentes-Retamal, D. Guzman-Rivera, H. Speisky, V. Castro-Castillo, M. Madrid-Rojas, J. Ferreira (Santiago, Chile) (10′)

5P. NEW ANTICANCER AGENTS (POSTERS)

  • Drozitumab, a fully humanised agonistic antibody against APO2L/TRAIL death receptor, DR5, exhibits anti-tumour activity in a PC-3 prostate cancer xenograft model. L. Giorgio, I. Zinonos, V. Liapis, A.P. Trotta, G. Buchanan, A. Evdokiou (Adelaide, SA, Australia)
  • Lipophilic cation derived of polihidroxy-benzoates as news cytotoxic molecules in human breast cancer cells. M. Catalán, S. Fuentes-Retamal, J.A. Jara , V. Castro-Castillo, M. Madrid-Rojas, M. Pavani, J. Ferreira (Santiago, Chile)
  • Netropsin analogues with alkylating moieties – new potential anticancer agents. D. Drozdowska, P. Samczuk, M. Bajda, P. Michalak (Bialystok, Poland)
  • Can Cu(II) Schiff bases be potencial anticancer drugs? K. Konariková, G. Perdikaris, H. Gbelcová, M. Švéda, T. Ruml, L. Laubertová, I. Žitnanová (Bratislava; Martin, Slovak Republic; Prague, Czech Republic)
  • Antiproliferative, apoptotic and necrotic effects Mentha longifolia (L). Hudson subsp typhoides (Briq) var. Typhoides on A549 lung cancer cells. O. Yumrutas, S. Oztuzcu, M. Pehlivan, M. Ulasli, M. Sokmen, I. Bozgeyik, E. Temiz, M.O. Cevik, H. Dagli, A. Arslan (Adiyaman; Gaziantep; Trabzon, Turkey)
  • Determination of anti-cancer effects of Evernia pronastri on MCF7 cancer cells. O. Yumrutas, C. Guven, Y. Ozay, I. Albeniz, M.A. Ahbab, I. Bozgeyik, A. Yildiz, H. Bagis, L.T. Sener (Adiyaman; Istanbul; Ankara, Turkey)
  • Response of monocytes and macrophages to temozolomide in mice. N. Berte, M. Eich, C. Koks, S. von Gool, B. Kaina (Mainz, Germany; Leuven, Belgium)
  • Inhibition of homologous recombination ameliorates anticancer drug-induced cell death. N. Berte, B. Kaina, T. Nikolova(Mainz, Germany)
  • Novel insights into the biology of endometrial stromal tumors and identification of potential therapeutic targets. J. Pzybyl, M. Kowalewska, A. Quattrone, B. Dewaele, V. Vanspauwen, J. Finalet-Ferreiro, M. Swierniak, E. Bakula-Zalewska, J.A. Siedlecki, M. Bidzinski, J. Cools, M. Debiec-Rychter (Warsaw; Gliwice; Kielce, Poland; Leuven, Belgium)

6. DRUG DELIVERY
Special Symposium Organized by D. Vetvicka

ROOM B, 13.00-17.30 – Monday, October 6

Chair Person: D. Vetvicka

  • Nanomedicine for cancer selective drug delivery; Advantages of the EPR effect and pitfalls. H. Maeda, H. Nakamura, J. Fang (Kumamoto, Japan) (30′)
  • Polymer-drug conjugates for targeted tumor therapy. T. Etrych, P. Chytil, E. Koziolová, M. Šírová, S. Hoffman, T. Müller, K. Mäder, B. Ríhová, K. Ulbrich (Prague, Czech Republic) (30′)
  • Bionanotechnology and novel targeted drug delivery systems. A. Syed (Edinburgh, UK) (30′)
  • Ultrasound-responsive systems for targeted cancer therapy. A.P. McHale, K. Curtis, N. Nomikou, B. Callan, J.F. Callan (Coleraine, Northern Ireland; London, UK) (30′)
  • Experimental topical photodynamic therapy of cancer with liposomal hydroxy-aluminium phthalocyanine. D. Vetvicka, M. Zadinova, M. Nekvasil, P. Jezek, J. Rakusan, M. Karaskova, J. Kralova, V. Kral, P. Pouckova (Prague; Rybitvi, Czech Republic) (30′)
  • Tumor regression after intravenous administration of novel tumour-targeted nanomedicines. C. Dufès (Glasgow, UK) (30′)
  • The Atomic Force Microscopy (AFM) in nanomedicine. D.A. Lamprou (Glasgow, Scotland, UK) (30′)
  • Polymer donors of nitric oxide for enhanced accumulation of anticancer agent in the solid tumor microenvironment. M. Studenovský, M. Šírová, B. Ríhová, K. Ulbrich (Prague, Czech Republic) (15′)

7. EXPERIMENTAL CHEMOTHERAPY

ROOM B, 17.45-19.30 – Monday, October 6

Chair Persons: L. Helson, S. Palakurthi, V. Treska

  • Oral formulation of a liposome breakdown product mitigates intravenous Moxifloxacin induced QTc prolongation in vivo. L. Helson, G. Shopp, A. Bouchard, M. Majeed, D. Salvail, W. Shaw (Boulder, CO,; Winsdor, NJ, USA; Sherbrooke, QC, Canada) (30′)
  • Nano polymer-cisplatin complexes for chemotherapy of ovarian cancer. S. Palakurthi, V.K. Yellepeddi (Kingsville, TX, USA) (30′)
  • The promise of sonodynamic therapy: using ultrasonic irradiation and chemotherapeutic agents as a treatment modality. M. Trendowski (Syracuse, NY, USA) (15′)
  • Portal vein embolisation with the application of haematopoietic stem cells in patients with primarily non-resectable colorectal liver metastases. V. Treska, V. Liska, J. Fichtl, D. Lysak, H. Mirka, J. Bruha, P. Duras (Pilsen, Czech Republic) (15′)

8. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM C, 08.00-09.50 – Monday, October 6

Chair Persons: S. Arbak, T. Dalianis, T. Theophanides

  • Human papillomavirus (HPV) and other biomarkers for prediction of clinical outcome in oropharyngeal squamous cell carcinoma (OPSCC). A. Näsman, C. Nordfors, N. Tertipis, N. Grün, J. Du, A. Ährlund-Richter, L. Haeggblom, L. Sivars, A. Vlastos, D. Lindquist, L. Hammarstedt Nordvall,L.Marklund, E. Munck-Wikland, T. Ramqvist, T. Dalianis (Stockholm; Umea, Sweden) (15’)
  • Infrared spectroscopy applied to cancer studies.T. Theophanides, J. Anastassopoulou (Athens Greece) (20’)
  • Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small cell lung cancer progression and patients’ overall survival. B.-H. Kuang, M.-Q. Zhang, L.-H. Xu, L.-J. Hu, H.-B. Wang, W.-F. Zhao, Y. Du, X. Zhang (Guangzhou; Zhengzhou, China, PR) (15’)
  • Altered epigenetic signature of circulating cell-free nucleosomes in colon and prostate cancer. M. Herzog, M. Chapelier, G. Cuvelier, K. Scoubeau, E. Josseaux, D. Pamart, M. Eccleston, J. Micallef (Namur, Belgium)(15’)
  • Diagnostic approach and prognostic factors in colorectal cancer. I.D. Tzeveleki (Thessaloniki, Greece) (15’)

9. CLINICAL CHEMOTHERAPY

ROOM C, 10.00-12.00 – Monday, October 6

Chair Persons: F. Muggia, R. Klapdor

  • Endometrial cancer: Building the systemic therapy backbone. F. Muggia (New York, NY, USA) (40’)
  • 16 years experience with an efficacy orientated sequential polychemotherapy of exocrine pancreatic cancer. R. Klapdor (Hamburg, Germany) (15’)
  • A clinical phase I study on administration of high dose sodium selenite as a treatment of cancer – the SECAR study. O. Brodin, M. Wallenberg, S. Misra, M. Björnstedt (Stockholm, Sweden) (25’)
  • Combinations of platinums and phytochemicals administered to ovarian tumour models. S. Althurwi, J.Q. Yu, P. Beale, C. Chan, F. Huq (Sydney, NSW, Australia) (10’)

10. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM C, 13.00-15.30 – Monday, October 6

Chair Persons: Y. Keisari, S. Kumar

  • Induction of anti-metastatic immune response by alpha radiation or electrochemical tumour ablation. Y. Keisari, H. Confino, I. Hochman , M. Efrati, M. Schmidt, V. Umansky, I. Kelson, R. Korenstein (Tel Aviv, Israel; Heidelberg; Mannheim, Germany) (30’)
  • Deconstructing inflammatory signaling pathway that promotes drug resistance and metastatic competence in cancer cells. K. Mehta (Houston, TX, USA) (30’)
  • Use of oncolytic viral vaccines to treat cancer. B.D. Lichty, Y. Wan, D.F. Stojdl, J.C. Bell, J.G. Pol, K.B. Stephenson, M.J. Atherton, B.W. Bridle (Hamilton; Ottawa; Guelph, ON, Canada) (30’)
  • The importance of the immunomodulatory protein, the progesterone induced blocking factor, in allowing cancer cells to escape immune surveillance and therapeutic considerations. J.H. Check (Camden, NJ, USA) (30’)

11. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM C, 15.45-18.00 – Monday, October 6

Chair Persons: D. Characiejus, F. Guadagni

  • Dendritic cell (DC) immunotherapy in gynaecological malignancies. A. Coosemans, I. Vergote, F. Amant, S.W. Van Gool (Leuven, Belgium) (30’)
  • In Vivo Imaging of antitumor lymphocytes. D. Characiejus, J. Jursenaite (Vilnius, Lithuania) (20’)
  • Antibody-based targeting of TNF-ligands for cancer therapy. E. Bremer (Groningen, the Netherlands) (30’)
  • Fatal bilateral radiation pneumonitis. S. El Sharouni (Utrecht, Netherlands) (20’)
  • Evaluation of the percentage of Th17, Treg and immature DC in the blood, drained LN, neoplastic and non-neoplastic tissues in colorectal cancer patients. R. Maciejewski, S. Radej, K. Torres, A. Torres, J. Kozak, A. Chroscicki, G. Wallner (Lublin, Poland) (15’)

12. TARGETING THE TUMOUR MICROENVIRONMENT(A)
Special Symposium Organized by I.P. Witz and Y. Keisari

ROOM D, 8.00-12.00 – Monday, October 6

Chair Persons: I.P. Witz, Y. Keisari

  • Metastasis and the metastatic microenvironment. I. P. Witz (Tel Aviv, Israel) (40’)
  • The mechanism of tumor cell trafficking. D. Naor (Jerusalem, Israel) (30’)
  • Mechanisms underlying the pro-tumorigenic effect of CXCL14-expressing cancer-associated fibroblasts. M. Augsten, E. Sjöberg,O. Frings, J. Frijhoff and A. Östman (Stockholm, Sweden) (30’)
  • Immunosuppression in melanoma microenvironment induced by chronic inflammation. V. Umansky, A. Sevko, J. Utikal (Heidelberg, Baden-Württemberg, Germany) (30’)
  • Do cancer cells impose epigenetic changes on normal fibroblasts? A colon-oriented preliminary inquiry. S. Lamprecht, J. Delinasios, A. Fich, N. Abu Freha (Beer-sheva, Israel; Kapandriti, Greece) (20’)
  • Galectin-1 in crosstalk between cancer cells and cancer-associated fibroblasts. K. Smetana Jr, B. Dvoránková , R. Mateu , J. Kucera , A. Mifková , Z. Fík , J.-M. Lehn , H.-J. Gabius (Prague, Czech Republic; Strasbourg, France; Munich, Germany) (30’)
  • The role of micro-RNAs in steroid induced apoptosis of hemopoietic cancers. S. Kfir, N.Haggiag, E. Yefenof (Jerusalem, Israel) (30’)

13. TARGETING THE TUMOUR MICROENVIRONMENT(B)
Special Symposium Organized by D. D. Spyropoulos and G. Sica

ROOM D, 13.00-17.00 – Monday, October 6

Chair Persons: D. D. Spyropoulos, G. Sica

  • Enzymatic remodeling of the tumor microenvironment enhances substantial changes in malignant cell phenotype and increased efficacy in combination with chemotherapy. H. M. Shepard , C. Thompson and J. Huang (San Diego, CA, USA) (30’)
  • Metabolic reprogramming during stromal aging and cancer progression. J. Son, E.H. Sarsour, J. Fussell, J. Lafin, A.L. Kalen, P.C. Goswami (Iowa City, IA, USA) (30’)
  • Tissue Banking and 3D ‘ex vivo‘ models for personalized medicine. J.E. Baatz, D.A. Newton, E.C. Riemer, C.E. Denlinger, E.E. Jones, R.R. Drake and D.D. Spyropoulos (Charleston, SC, USA) (30’)
  • Breast cancer-associated fibroblasts promote tumor cell migration: crucial role of stearoyl-CoA desaturase 1 and paracrine signalings. C. Angelucci, G. Maulucci, A. Colabianchi, F. Iacopino, A. D’Alessio, A. Maiorana, V. Palmieri, M. Papi, M. De Spirito, A. Di Leone, R. Masetti, G. Sica (Rome, Italy) (30’)
  • Cell type – specific gene expression analysis at the infiltrative margins of glioma. A. Dovas, B. Gill, D. Pisapia, H. Malone, H. Goldstein, L. Lei, A. Sonabend, J. Yun, J. Samanamud, J. Sims, M. Banu, A.F. Teich, S. Sheth, G. McKhann, M. Sisti, J.N Bruce, P. Sims and P. Canoll (New York, NY, USA) (15’)
  • Immuno-modulatory properties of cancer-associated fibroblasts. L. Gorch, T. Hellevik, T.B. Stuge, I. Martinez-Zubiaurre (Tromso, Norway) (15’)
  • Tumor microenvironment of metastasis in head and neck cancer. S. Koontongkaew (Prathum thani, Thailand) (20’)
  • Cell-cell interactions between transformed and non-transformed epithelial cells: the role of e-cadherin. N.A. Gloushankova, S.N. Rubtsova, I.Y. Zhitnyak (Moscow, Russia) (20’)

13P. TARGETING THE TUMOUR MICROENVIRONMENT (POSTERS)

  • Extracellular matrix of galectin-1-exposed dermal and tumor-associated fibroblasts favors growth of human umbilical vein endothelial cells and human dermal keratinocytes. P. Gal, L. Varinska, B. Dvorankova, V. Perzelova, J. Mojzis, L. Mirossay, S. Andre, H. Kaltner, H-J. Gabius, K. Smetana Jr (Kosice; Bratislava, Slovak Republic; Prague, Czech Republic; Munich, Germany)
  • Tryptase- and chymase -possitive mast cells in thyroid cancer. K. Ivanova, E. Onal, J. Ananiev, A. Zdraveski, I. Rachkov, M. Gulubova (Stara Zagora, Bulgaria)
  • Analysis of the interaction of normal human fibroblasts and different cancer cells in mixed cultures by xcelligence studies. D. Szabó, G. Spengler, J. Molnár, G. Tax, K. Szabó, L. Rovó (Szeged, Hungary)

14. CIRCULATING TUMOR CELLS
Special Symposium Organized by M.Rigaud

ROOM D, 17.15-19.35  – Monday, October 6

Chair Persons: M. Rigaud, S.S. Martin

  • Targeting microtentacles on circulating breast tumor cells to reduce metastasis. A.E. Boggs, M.S. Charpentier, M.I. Vitolo, R.A. Whipple, K. Thomson, L. Bhandary, K. Chakrabarti, O.B. Ioffe, Y. Lu, G.B. Mills and S.S. Martin (Baltimore, MD, USA) (30’)
  • High throughput few and single cell expression profiling and the characterization of circulating tumor cells. M. Kubista, R. Sjöback, M. Jindrichova, E. Rohlova, V. Rusnakova, S. Hauch, B. Aktas, M. Tewes, M. Bredemeier, S. Kasimir-Bauer (Langenhagen; Essen, Germany) (30’)
  • EML4-ALK investigation in mNSCLC patient CTCs using an in vivo procedure. G. Gallerani, M. Zoli, P. Fici, S. Bravaccini, M. Tumedei, A. Delmonte, M.A. Burgio,C. Casadei, F. Fabbri (Bologna; Ferrara; Meldola, Italy) (15’)
  • EMT ratio as CTC aggressiveness index. P. Fici, G. Gallerani, M. Rigaud, F. Fabbri (Meldola; Bologna, Italy) (15’)
  • A new medical device for in vivo isolation of circulating tumor cells – clinical validation and overview of potential target. S. Herold, L. Gasiorowski, P. Nowaczyk, A. Schumann, G.Theil, J. Tucholski, B. Nowack, T. Krahn, W. Dyszkiewicz, D. Murawa, K. Lücke (Potsdam, Germany) (25’)
  • A microfluidic CTC sorting strategy using self-assembled magnetic particles. E. Tulukguoglu, C. Bureau,  K. Perez-Toralla, S. Descroix, L. Malaquin,  J.Y. Pierga, F.C. Bidard, J.L. Viovy (Paris; Fluigent; France) (15′)

14P. CIRCULATING TUMOR CELLS (POSTERS)

  • CEA mRNA-positive circulating/disseminated tumor cells in the peripheral blood/bone marrow predict poor prognosis in surgically treated non-small cell lung cancer patients. J. Klein, A. Prokopová, J. Srovnal, J. Chudácek, I. Grygárková, J. Škarda, J. Andel, J. Duša, M. Hajdúch (Olomouc, Poland)

15. CARCINOGENESIS; VIRAL ONCOGENESIS

ROOM E, 08.00-09.30 – Monday, October 6

Chair Persons: W. Engström, A.R. Young

  • Photoprotection by sunscreens and skin cancer. A.R. Young (London, UK) (30’)
  • The HALIFAX project – an attempt to assess the carcinogenicpotential of low dose exposures to chemical mixtures in the environment. W. Engström, T. Hultman, L. Lowe (Uppsala, Sweden; Nova Scotia, Canada) (15’)
  • A metal exposured cohort study in the largest metal workers population in the world. Y. Bai (Lanzhou, Gansu, PR China) (15’)

16. ALTERNATIVE AND COMPLEMENTARY MEDICINE IN CANCER TREATMENT
Special Symposium Organized by S. Pathak

ROOM E, 9.40-12.00 – Monday, October 6

Chair Persons: B.B. Aggarwal, S. Pathak

  • Anti-inflammatory life style for prevention and treatment of cancer: Let food be thy medicine and medicine be thy food. B.B. Aggarwal, A.K. Tyagi, L. Deb, S. Prasad (Houston, TX, USA) (45’)
  • Complimentary and alternative medicine and integrative oncology. S. Pathak (Houston, TX, USA) (40’)
  • The Banerji protocols: for the treatment of intracranial space occupying lesions and specifically GBM-IV. P. Banerji, P. Banerji (West Bengal, India) (30’)

17. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM E, 13.00-16.00 – Monday, October 6

Chair Persons: T. Efferth, J. Molnar

  • Inhibition of P-glycoprotein in cancer cells by synthetic and natural compounds. T. Efferth, M. Zeino, M. Volm (Mainz; Heidelberg, Germany) (40’)
  • Targeting BAG-1-mediated protein interactions to overcome BRAF inhibitor resistance. M. Enthammer, M. Thurner, S. Khalid, H. Stuppner H, R.I. Cutress, J. Troppmair (Innsbruck, Austria; Southampton, UK) (30’)
  • “Quadrugnostic” nanoparticles for overcoming anticancer drug resistance and for diagnostics. R. Edelmana, Y.G. Assarafb, R. Goldschmidta, I. Levitzkia, T. Shahara, A. Slavkina, Y. D. Livney (Haifa, Israel) (30’)
  • Cisplatin-associated protein contributes to cisplatin resistance and malignancy in thyroid carcinoma. A. Derwiysh, R. Arsenic, H. Lage (Berlin, Germany) (15‘)
  • Induction of activating transcription factor 3 is associated with cisplatin responsiveness in NSCLC. J. Bar, D. Stewart, G.D. Goss, J. Villeneuve, J. Dimitroulakos (Ottawa, Ontario, Canada) (15’)

18. THE SUGAR CODE IN TUMOR BIOLOGY/PATHOLOGY: PRINCIPLES AND EXAMPLES
Special Symposium Organized by H.J. Gabius

ROOM E, 16.00-19.00 – Monday, October 6

Chair Persons: H.J. Gabius, K. Kayser, J. Kopitz, K. Smetana Jr

  • Introduction to the sugar code in tumor biology/pathology: Principles and examples. H.J. Gabius, K. Kayser, J. Kopitz, K. Smetana Jr (Munich; Berlin; Heidelberg, Germany; Prague, Czech Republic) (30’)
  • A primer to the function of glycoproteins and glycolipids in tumor biology. J. Kopitz (Heidelberg, Germany) (30’)
  • How human lectins translate the sugar code. H.J. Gabius (Munich, Germany) (30’)
  • Galectins in squamous cell carcinomas. K. Smetana Jr (Prague, Czech Republic; Munich, Germany) (30’)
  • Structural entropy and lectins: partners in analyzing biological information at the cellular level. K. Kayser (Berlin, Germany) (30’)

19. CANCER GENOMICS. MICROARRAY TECHNOLOGY

ROOM F, 8.00-10.00 – Monday, October 6

Chair Persons: D. Anderson, D.-T. Bau

  • Demystifying the dark matter of the human proteome: Implications for novel biomarkers and drug targets. R. Narayanan (Boca Raton, FL, USA) (30’)
  • Quantitative proteomic profiling of fromalin-fixed paraffin-embedded (FFPE) prostate cancer tissues. D. Iglesias-Gato (Copenhagen, Denmark) (20’)
  • Translational network for predictive, preventive, personalized and participatory cancer study. D-T Bau, C-W Tsai, W-S Chang, C-M Hsu (Taichung, Taiwan, ROC) (30’)
  • Profiling of chromosomal changes in potentially malignant and malignant oral mucosal lesions from South and South-East Asia using Array – Comparative genomic hybridization. M.S. Lunde, E. Roman, S. Warnakulasuriya, R. Mehrotra, J. Laranne, E.N. Vasstrand and S.O. Ibrahim (Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland) (15’)

20. CANCER GENOMICS. MICROARRAY TECHNOLOGY

ROOM F, 10.00-12.30 – Monday, October 6

Chair Persons: R. Narayanan, C. Nicolini

  • Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) Assay: Implications for improving cancer diagnostics. D. Anderson, M. Najafzadeh, R. Gopalan, N. Ghaderi, A. J. Scally, S.T. Britland, B.K. Jacobs, P.D. Reynolds, J. Davies, A. L. Wright, S. Al-Ghazal, D. Sharpe, M.C. Denyer (Bradford, West Yorkshire, UK) (30’)
  • Clinical cancer proteomics: models for personalized medicine. A.A. Alaiya (Riyadh, Saudi Arabia) (30’)
  • Determination of protein-protein interaction for cancer control via mass spectrometry and conductimetry of nappa-snap microrrays. C. Nicolini, E. Pechkova (Bergamo, Italy) (30’)
  • LB based nanocrystallography at the frontiers of cancer proteomics. E. Pechkova, C. Nicolini (Genova, Italy) (20’)
  • The study of genomic contribution in Taiwan head and neck cancers. C.-W. Tsai, C.-M. Hsu, W.-S. Chang, D.-T. Bau (Taichung,Taiwan) (15’)

20P. CANCER GENOMICS. MICROARRAY TECHNOLOGY (POSTERS)

  • The influence of silver nanoparticles (AgNPs) on the expression of proliferation and apoptosis-related genes of glioblastoma multiforme (GBM) cells cultured on in ovo model. M. Szmidt, A. Stankiewicz, P. Lisowski, J. Sokolowska, P. Sysa, K. Urbanska (Warsaw, Poland)
  • Genomic characterization of endometrial stromal sarcomas using Array CGH. E. Smolle, K. Flicker, F. Moinfar, M. Speicher, J. Haybaeck (Graz, Austria)

21. GENOMIC INSTABILITY AND CANCER (DNA REPAIR)
Special Symposium Organized by A.A. Wani

ROOM F, 13.00-19.30 – Monday, October 6

Chair Persons: A.A. Wani, R.M. Snapka

  • Chromatin structure and ionizing radiation signaling. T.K. Pandita (Houston, TX, USA) (40’)
  • Ubiquitination and deubiquitination of DNA repair factors : Modulation by modification. J. He, Q. Zhu, G. Wani, N. Sharma, C. Han, J. Qian, K. Pentz, Q. Wang and A.A. Wani (Columbus, OH,USA) (30’)
  • DNA damage-induced regulation of base excision repair protein stability and ARTD1 activation. R.W. Sobol (Pittsburg, PA, USA) (30’)
  • Regulatory mechanisms of transcription-coupled DNA repair. S. Malik, P. Chaurasia, R. Sen, S. Lahudkar, G. Durairaj, B. Uprety, S. R. Bhaumik (Carbondale, IL, USA) (40’)
  • Single stranded DNA binding protein 1 recruits TERT to telomeres. R.K. Pandita, D. Udayakumar, C.R. Hunt, N. Horikoshi, T.K. Pandita (Houston, TX, USA) (40’)
  • Thymoquinone inhibition of autophagy causes growth inhibition and caspase-independent death of glioblastoma cells. R.M. Snapka, I.O. Racoma, W.H. Meisen, Q.-E. Wang, B. Kaur, A.A. Wani (Ohio,USA) (30’)
  • ROS mechanisms mediate the inhibition of oral cancer by avocado extract. H. Ding, B. Casto, Y. Deng, K. Grill, W. Duan, N. Zhang, S. Cole, K. La Perle, X. Pan, A.D. Kinghom, S.M. D’Ambrosio (Columbus , OH, USA) (25’)
  • DNA damage responses in ovarian cancer stem cells. A. K. Srivastava, C. Han, R. Zhao, T. Cui, Q.-E. Wang (Columbus , OH, USA) (30’)
  • Oxidative genome damage repair deficiency in a human DNA glycosylase NEIL2 variant: Potential linkage to lung cancer susceptibility. T. Hazra (Galveston, TX, USA) (30’)

Tuesday, October 7


22. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-12.00 – Tuesday, October 7

Chair Persons: R.M. Hoffman, F.E. Ahmed, P. Kumar

  • Cell cycle decoy with Salmonella typhimurium A1-R to convert tumors from chemo-resistant to sensitive. S. Yano, M. Zhao, T. Fujiwara, R.M. Hoffman (San Diego, CA, USA; Okayama, Japan) (30’)
  • Desmoglein 3 acts as a mechanosensor in response to environmental mechanical property. H. Wan, F. Kenny, J. Connelly (London, UK) (20’)
  • Redox regulation of the cell cycle in health and disease. P.C.Goswami (Iowa City, IA, USA) (30’)
  • A new target of Ras-signaling pathway that promotes angiogenesis in aggressive breast cancer. B.K. Ray, A. Ray (Columbia, MO, USA) (30’)
  • RT-QPCR and its application to medicine and molecular biology. F.E. Ahmed, N.C. Ahmed (Greenville, NC, USA) (30’)
  • A physiological in vivo model for neuroectodermal child-cancer. I.Hultman, L. Ährlund-Richter (Stockholm, Sweden) (30’)
  • The expression and the role of glutamate receptors in cancer. A. Stepulac (Lublin, Poland) (30’)
  • Wnt signaling as a target of anti-breast cancer drug discovery.  V.L. Katanaev (Lausanne, Switzerland) (25′)

22P. MOLECULAR AND CELLULAR BIOLOGY OF CANCER (POSTERS)

  • Investigating the mechanism of eIF3e-regulated epithelial-to-mesenchymal transition. G. Desnoyers, L. Frost, S.M. Lewis (Moncton; St. John, NB; Halifax, NS, Canada)
  • Evaluation of multiple stemness markers in normal thyroid and in thyroid carcinoma (TC) specimens. F. Iacopino, M. Raffaelli, M.A. Puglisi, S. Ronti, C. De Crea, G. Fadda, C.P Lombardi, R. Bellantone, G. Sica (Rome, Italy)
  • Expression levels of WNT genes in cervical cancer-derived cell lines: WNT7A is downregulated and its overexpression inhibits cell proliferation. A. Aguilar-Lemarroy, M. Ramos-Solano, I.D. Meza-Canales, L.A. Torres-Reyes, L. Alvarado-Ruíz, M. Alvarez-Zavala, P. Gariglio, L.F. Jave-Suarez (Guadalajara, Jalisco; Mexico City, Mexico)
  • The expression of transcription factor grainyhead-like 2 is diminished in cervical cancer. L.A. Torres-Reyes, A. Aguilar-Lemarroy, L. Alvarado-Ruiz, P. Piña-Sánchez, M.G. Martínez-Silva, M. Ramos-Solano,V. Olimón-Andalón, A. Bravo-Cuellar, L.F. Jave-Suarez (Guadalajara, Jalisco; Mexico City’ Culiacán, Sinaloa, Mexico)
  • Native type IV collagen induces migration through a PI3K/Akt-dependent pathway in MDA-MB-231 breast cancercells. E. Reyes-Uribe, P. Cortes-Reynosa, E. Perez-Salazar (México DF, México)
  • Role of LOXs and COX-2 in FAK activation and cell migration induced by linoneic acid in MDA-MB-231 cancer cells. N. Serna Marquez, S.V. Comonfort, O.G. Hernández, N.N. Tito, E. Pérez Salazar (México DF, México)
  • Are the centrioles sensory centres in living cells? Impact to mechanism of cancer (a hypothesis). A.T. Atanasov (Stara Zagora, Bulgaria)
  • The influence of silver nanoparticles (AgNPs) on mitochondrial ultrastructure of glioblastoma multiforme (GBN) cells cultured on in ovo model. K. Urbanska, J. Sokolowska, M. Szmidt, P. Sysa (Warsaw, Poland)
  • Study of EGFR expression in canine mast cell tumors: possible implications for therapy. A.Liberal, F.L. Queiroga, I. Pires, M.I. Carvalho, J. Prada (Vila Real, Portugal)
  • Study of EGFR immunoexpression in canine melanocytic tumors. Clinical and therapeutic implications. C. Ferreira, L. Resende, I. Pires, J. Prada, F.L. Queiroga (Vila Real, Portugal)
  • Differential expression profile of mucins in humanhead and neck cancer celllines. K. Utispan, S. Koontongkaew (PathumThani, Thailand)
  • Characterization of the molecular biology of EGFRvIII in the populational context in DK-MG cell line. W.J. Stec, K. Rosiak, P. Siejka, J. Peciak, M. Banaszczyk, K. Bigoszewska, P. Sylwester, Stoczynska-Fidelus, P. Rieske (Lodz, Poland)
  • The role of cellular prion protein in schwannoma and other Merlin-deficient tumours. L. Provenzano,S. Ammoun, C.O Hanemann (Plymouth, Devon, UK)
  • Developing tools to study the role of Geminin in cancer and development. S. Champeris Tsaniras, A.D. Giannou, M. Chol, K. Anastassiadis, G. Stathopoulos, Z. Lygerou, S. Taraviras (Patras, Greece; Dresden, Germany)
  • Overview on electron emission from hormones and subsequent biological consequences. N. Getoff (Vienna, Austria)

23. HOX GENES IN CANCER
Special Symposium Organized by C. Aukim-Hastie and R. Morgan

ROOM A, 13.00-16.20 – Tuesday, October 7

Chair Persons: R. Morgan, C. Aukim-Hastie

  • Introduction: R. Morgan(10’)
  • HOX transcription factors are potential targets and markers in malignant mesothelioma. R. Morgan, S. Gray, C. Gillett, Z. Tabi, F. Launchbury, J. Spicer, K. Harrington, H.S. Pandha (Guilford; London; Cardiff, UK) (20’)
  • HOX genes in head and neck squamous cell carcinoma (HNSCC). K.D. Hunter (Sheffield, UK) (20’)
  • Targeting the HOX transcription factors and CD71 in multiple myeloma. T.R. Daniels, I.I. Neacato, J.A. Rodríguez, H.S. Pandha, R. Morgan, M.L. Penichet (Los Angeles, CA, USA; Guildford, UK) (20’)
  • Giving birth to blood stem cells, in vitro: HOXB4 promotes hematopoiesis during pluripotent stem cell differentiation by increasing the pool of hemogenic endothelium cells. N. Teichweyde, L.Kasperidus, S. Skibbe, P. Horn, H. Klump (Essen, Germany) (20’)
  • Investigating the role of homeobox genes in breast cancer stem cell function. M. Shah, R. Emes,A. Grabowska, C. Allegrucci (Loughborough; Nottingham, UK) (20 ‘)
  • Candidate drug screening in HOX-related models of AML. C.L. Burt, L.M.J. Kettyle, N.M. Mulgrew, J.M. Ramsey, G.J. Dickson, A. Thompson (Belfast; London, UK) (20’)
  • The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the MIR-221&222-C-FOS pathway. M.C. Errico, F. Felicetti, L. Bottero, G. Mattia, N. Felli, M. Petrini, M. Bellengh, H.S. Pandha, R. Morgan, A. Carè(Rome, Italy; Guilford, UK) (20’)
  • HOX gene expression in ovarian cancer. A. Michael, Z.L. Kelly, C.S. Moller-Levet, H. Pandha, R. Morgan (Guildford,UK) (20’)
  • Closing remarks : R. Morgan(5’)

24. ONCOGENES; TUMOR SUPPRESSOR GENES; GROWTH FACTORS; SIGNAL TRANSDUCTION

ROOM A, 16.30-19.45 – Tuesday, October 7

Chair Persons: T.G. Cotter, R. Todorova

  • Oncogene driven redox survival signalling in tumour cells. T.G. Cotter, J. Stanicka, W. Laundry (Cork, Ireland) (30’)
  • Functional domains and IPD targeted therapy for Ewing’s sarcoma. R. Todorova (Sofia, Bulgaria) (30’)
  • The oxidative stress-associated SRC activator and C-SRC tyrosine kinase- novel targets in the mechanism of photodynamic therapy. M. Wozniak, K. Dus-Szachniewicz, B. Ziólkowska, P. Ziólkowski (Wroclaw, Poland) (10’)
  • Identification and targeting pathways involved in the development of Merlin-deficient tumours. S. Ammoun, L. Provenzano, L. Zhou, M.C. Schmid, C.O Hanemann (Plymouth, Devon, UK) (40’)
  • Thioredoxin reductases 1: A key member in metabolism newly identified as prognostic and targetable in non-small cell lung cancer (NSCLC). Y. Zhang, M. Zhou, H. Zeng, W. Jiang, Y. Li, W. Ma, Y. Qiu, R. Guan, C. Zhou, L. Zeng, L. Liu, Y. Xiong, N. Yang (Changsha; Beijing, China PR) (10’)
  • Gastric cancer in Morocco: Novel therapeutic targets. H. Amrani Hassani Joutei, N. Marchoudi, W. Mahfoud, I. Sadaoui, H. Lebrazi, T. Fechtali, H. Benomar (Casablanca; Mohammedia, Morocco) (30’)

24P. ONCOGENES; TUMOR SUPPRESSOR GENES; GROWTH FACTORS; SIGNAL TRANSDUCTION (POSTERS)

  • Annatto (Bixaorellana)-derived d-tocotrienol supplementation suppresses PIK3CA oncogene expression in 2- and 4-cell embryos of nicotine-induced mice. S.S. Mohd Mutalip, M.H. Rajikin, S. Ab Rahim, N.A.M. Noor Khan, A. Trias, B. Tan (Selangor, Malaysia; Hadley, MA, USA)
  • The importance of immunohistochemical distributions of IGF, TGF-B, PDGF and PCNA on uterine smooth muscle tumors. M. Ozgul, T. Turkoz Uluer, M. Sanci, S. Sayhan, S. Inan (Manisa; Izmir, Turkey)

25. SERUM MARKERS IN DIAGNOSIS AND THERAPY
ISOBM. Special Symposium Organized by R. Molina and V. Barak

ROOM B, 8.00-10.00 – Tuesday, October 7

Chair Persons: R. Klapdor, R. Molina, V. Barak

  • Comparison of 3 different immunoassays for determination of CA 19-9 in pancreatic cancer patients – a new aspect of potentially clinical relevance. R. Klapdor, M. Bahlo (Hamburg, Germany) (20’)
  • Tumor markers in lung cancer, a tool for early diagnosis? R. Molina, R.M. Marrades, J.M. Augé, J.M. Escudero, N. Viñolas, N. Reguart, J. Ramirez, X. Filella, L. Molins, A. Agusti (Barcelona,Spain) (30’)
  • Prognostic significance of tumor markers in breast cancer. V. Barak, B. Uziely, A. Hubert, I. Kalichman, R. Einarsson, T. Peretz (Jerusalem, Israel) (30’)
  • Liquid biopsy – new perspectives for prediction and monitoring of therapy response in cancer patients. S. Holdenrieder (Bonn, Germany) (30’)

26. SERUM MARKERS IN DIAGNOSIS AND THERAPY

ROOM B, 10.10-12.00 – Tuesday, October 7

Chair Persons: R. Klapdor, S. Holdenrieder, V. Barak

  • Biomarkers for malignant melanoma –treatment response assessment and metastasis prediction. V. Barak, S. Frenkel, S. Merims, M. Lotem, T. Peretz, I. Kalichman, J. Pe’er (Jerusalem, Israel) (30′)
  • Histone modifications in circulating nucleosomes as potential new biomarkers in cancer. U. Gezer, E.E. Yörüker, M. Keskin, S. Holdenrieder, N. Dalay (Istanbul, Turkey) (15’)
  • Roles of caveolin-1 and cyclooxygenase 2 in kidney, ureter, bladder and prostate cancers. W.-S. Chang, C.-W. Tsai, C.-M. Hsu, D.-T. Bau (Taichung, Taiwan) (15’)
  • Practical experience of the fecal hemoglobin immunochemical test in a colorectal cancer screening program. J.M. Auge (Barcelona, Spain) (30’)
  • Determination of neopterin, kynurenine and tryptophan as immune system activation markers in various biological fluids. L. Kujovská Krcmová, B. Cervinková, D. Solichová, B. Melichar, L. Sobotka, P. Solich (Králové, Czech Republic) (15’)

27. SERUM MARKERS IN DIAGNOSIS AND THERAPY

ROOM B, 13.00-15.00 – Tuesday, October 7

Chair Persons: K.J. Syrjänen, O. Topolcan

  • A non-invasive diagnosis of gastric cancer (GC) precursors (Helicobacter pylori infection and atrophic gastritis) by an ELISA-test (GastroPanel®) measuring 4 stomach-specific biomarkers in the blood. K.J. Syrjänen (Barretos-SP, Brazil) (40’)
  • Prognostic value of tumor markers in malignant melanoma. O. Topolcan, I. Treskova, J. Windrichova, V. Treska, J. Kinkorova, R. Kucera and T. Kydlicek (Plzen, Czech Republic) (15’)
  • Horizon 2020. J. Kinkorová (Pilsen, Czech Republic) (10’)
  • The clinical significance of acute phase proteins levels in non small cell lung cancers. N. Tsoukalas, C. Giaginis, M. Tolia, M. Kyriakou, I. Kostakis, E. Bournakis, A. Papakostidi, K. Ballasis, S. Theocharis, C. Chrystophyllakis, K. Liaskonis  (Athens, Greece) (10’)
  • Cytokine profiles of benign and malignant thyroid disease. X. Provatopoulou, D. Georgiadou, E. Kalogera, G. Georgiou, T.N. Sergentanis, G.N. Zografos, A. Gounaris (Athens, Greece) (10’)

27P. SERUM MARKERS IN DIAGNOSIS AND THERAPY (POSTERS)

  • Identification of dihydrolipoamide dehydrogenase as a novel target of autoantibodies in patients with endometrial cancer: a proteomic analysis. K. Yoneyama, R. Shibata, A. Igarashi, S. Kojima, Y. Kodani, K. Nagata, K. Kurose, R. Kawase, T. Takeshita, S. Hattori (Tokyo, Japan)
  • Predictive role of serum tumor markers in patients with advanced-stage NSCLC treated with EGFR-TKI. O. Fiala, M. Pesek, J. Finek, L. Benesova, M. Minarik, Z. Bortlicek, O. Topolcan (Prague, Czech Republic)
  • Biomarkers of metastatic bone process – test of multiplex assay. J. Windrichova, R. Fuchsova, O. Topolcan, M. Prazakova, J. Finek (Prague, Czech Republic)
  • Determination of important biomarkers using modern UHPLC technology. B. Cervinková, L. Kujovská Krcmová, J. Plíšek, D. Solichová, P. Solich (Králové, Czech Republic)
  • Serum level of tumor markers and albumin as prognostic factors for overall survival in gastric cancer. K. Angelov, T. Sedloev, K. Grozdev, M. Vasileva, M. Sokolov, G. Todorov (Sofia,Bulgaria)
  • The clinical importance of serum CEA and CA 19-9 levels in non small cell lung cancers. N. Tsoukalas, C. Giaginis, I. Kostakis, M. Kiakou, M. Tolia, E. Bournakis, A. Papakostidi, K. Ballasis, S. Theocharis, C. Chrystophyllakis, K. Liaskonis (Athens, Greece)
  • Exploring the role of dehydroepiandrosterone sulphate (DHEAS) in the mammary gland by liquid chromatography–mass spectrometry. E. Kalogera, P. Pistos, S. Athanaselis, M. Stefanidou, X. Provatopoulou, P. Grigoropoulos, C. Spiliopoulou, A. Gounaris (Athens, Greece)

28. IMAGE-GUIDED RADIOTHERAPY
Special Symposium of the International Geriatric Radiotherapy Group (IGRG)
Organized by N.P. Nguyen

ROOM B, 15.15-19.00 – Tuesday, October 7

Chair persons: N.P. Nguyen, U. Karlsson

  • Elderly and cancer care. U. Karlsson (Marshfield, WI, USA)(40’)
  • The role of image-guided radiotherapy in dose escalation for locally advanced non-small cell lung cancer. A. Chi, N.P. Nguyen (Morgantown, WV, USA) (30’)
  • Treatment planning comparison between HDR & IMRT for early stage breast cancer using SAVI technique. S.R. Bose, N.P. Nguyen (Washington, DC, USA) (30’)
  • The potential of image-guided radiotherapy for normal organs sparing in patients with locally advanced head and neck cancer. N.P Nguyen, A. Chi, V. Vinh-Hung, O. Gorobets, S. Bose, U. Karlsson (Washington, DC, USA) (25’)
  • Feasibility of image-guided radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. N.P. Nguyen, S. Kratz, A. Chi, J. Vock, P. Vos, W. Shen, V. Vinh-Hung, L. Ewell, S. Jang, G. Altdorfer, U. Karlsson, J. Godinez, W. Woods, S. Dutta, F. Ampil (Washington, DC; Tucson, AZ; Morgantown; Parkersburg, WV; Greenville, NC; Marshfield, WI; Jacksonville, FL; Salisbury, MD; Shreveport, LA; San Antonio, TX, USA; Martinique, France; Lindenhofspital, Switzerland) (25’)
  • Studies on human cells irradiated with two radiation modalities (IMRT or conventional RT) show different molecular and cellular responses: public health implications. F.E. Ahmed, P.W. Vos, R.R. Allison, C. Jeffries (Greenville; Chapel Hill, NC, USA) (30’)

29. EXPERIMENTAL CHEMOTHERAPY

ROOM C, 08.00-12.15 – Tuesday, October 7

Chair Persons: G. Ciarimboli, J. Haybaeck

  • Organic cation transporters mediate cisplatin and oxaliplatin side effects. G. Ciarimboli, J. Sprowl, A. Hucke, A. Zehnhoff-Dinnesen, A. Sparreboom, E. Schlatter(Münster, Germany; Memphis, TN, USA) (30’)
  • Pitfalls of mouse cancer models (know your mouse). K. Helke (Charleston, SC, USA) (30’)
  • Intergrative oncology: Use of natural substances in oncology treatment: Useful,possible, valid. M. Bonucci (Rome, Italy) (40’)
  • The JAK/STAT pathway is activated in gallbladder carcinoma. E. Lederer, J. Petzold, R. Reihs, C. Ernst, K. Bettermann, R. Moriggl, M.Schlederer, L. Kenner, S. Lax, P. Obrist, Y.N. Park, K.Sik Kim, S. Flechsig, J. Hoffmann, J. Haybaeck (Graz; Vienna; Zams, Austria; Seoul, South Korea; Berlin, Germany) (30’)
  • Acetylcarnitine potentiates the anticarcinogenic effects of butyrate. I. Elimrani, S. Dionne, D. Saragosti, I. Qureshi, L. Levy, E. Delvin, E.G. Seidman (Montreal, Quebec, Canada) (15’)
  • Morphine, melatonin, marijuana, magnolia and myrrh as the “five m” schedule in the treatment of cancer pain and the possible dose-dependency of the antitumor and analgesic effects of the pineal hormone melatonin. P. Lissoni, G. Porro, G. Messina, E. Porta, F. Rovelli, M.G. Roselli, F. Brivio (Milan, Italy) (20’)
  • Placental alkaline phosphatase to treat tumors as well as associated weight loss and muscle wasting. Z. Kiss (Austin, MN; La Jolla, CA, USA; Budapest, Hungary) (30’)
  • Invitro and pH sensitive properties of calcium carbonate nanocrystal as novel delivery carrier for tamoxifen in estrogen receptor breast cancer cell line MCF-7. A.S. Kamba, A.L. Argungu, A.B.Z. Zuki (Serdang, Selangor, Malaysia) (15’)
  • A psychobiological approach in the treatment of advanced cancer-related pleasure deficiency. G. Messina (Milano, Italy) (20’)

29P. EXPERIMENTAL CHEMOTHERAPY (POSTERS)

  • Targeting endometrial stromal sarcoma cell via histone deacetylase and the PI3K/Akt/mTOR pathway. P. Ouan, F. Moinfar, I. Kufferath, M. Absenger, T. Kueznik, H. Denk, K. Zatloukal, J. Haybaeck (Graz, Linz, Austria)
  • Systematic study on the cytostatic and/or cytotoxic effects of over twenty anticancer drugs: the crucial importance of the analytical approach and the data processing. D. Ivanova, D. Lazarova, E. Georgieva, I. Aoki, Z. Zhelev, R. Bakalova (Stara Zagora; Sofia, Bulgaria; Chiba, Japan)
  • Use of metronomic protocols in the treatment of several end stage dog cancers: a new approach and implications as a model for human disease. H. Gregório, I. Pires, J. Prada, F.L.Queiroga (Vila Real, Portugal)
  • Effect of complex of precursors and modulator of ubiquinone biosynthesis and ubiquinone-10 in combination with doxorubicin on rat Guerin’s carcinoma and Walker-256 mammary carcinoma growth rate. O.B. Kuchmenko, D.M. Petukhov (Kiev, Ukraine)
  • Early preoperative administration of monoclonal antibody against transforming growth factor beta -1 does not influence the regeneration of liver remnant volume after resection – experiment in swine. V. Liska, V. Treska, J. Bruha, O. Vycital, H. Mirka (Pilsen, Czech Republic)
  • Monoclonal antibodies against transforming growth factor Beta 1 as potential biological therapy does not influence liver regeneration in toxic liver injury – experiment on large animal. V. Liska, V. Treska, J. Bruha, O. Vycital, H. Mirka (Pilsen, Czech Republic)

30. CYTOGENETICS AND GENETICS

ROOM C, 13.00-15.30 – Tuesday, October 7

Chair Persons: D.-T. Bau, E. De Breakeleer, S. Ingvarsson

  • BAC analysis of chromosomal translocation breakpoints: an efficient strategy for identifying new candidate genes in malignant hemopathies. N. Douet-Guilbert, E. De Breakeleer, C. Tous, N. Gueganic, M.J. Le Bris, A. Basinko, M. De Braekeleer (Brest, France) (30’)
  • The genetic landscape of familial breast cancer in Iceland. S. Ingvarsson (Reykjavik, Iceland) (30’)
  • Identification of PRRC1-MLL, a novel fusion gene, in a case of therapy-related acute lymphoblastic leukemia. N. Douet-Guilbert, C. Meyer, J.R. Eveillerd, V. Ugo, M.J. Le Bris, A. Basinko, F. Morel, R. Marschalek, M. De Braekeleer (Brest, France; Mail, Germany) (15’)
  • Effects of Ataxia telangiectasia mutated (ATM) genotypes and personal smoking status on lung cancer risk in Taiwan. S.-C. Wang, W.-S. Chang, C.-M. Hsu, C.-W. Tsai, D.-T. Bau (Taichung, Taiwan, ROC) (15’)
  • Evaluation of the contribution of methylenetetrahydrofolate reductase genotypes to Taiwan breast cancer. C.-Y. Huang, W.-S. Chang, C.-W. Tsai, C.-M. Hsu, C.-L. Hsiao, D.-T. Bau (Taichung; Taipei, Taiwan, ROC) (10’)
  • The genotype/phenotype study for the role of caveolin-1 in gastrointestinal tract cancers. C. M. Hsu, W.-S. Chang, H.-X. Ji,C.-W. Tsai, D.-T. Bau (Taichung, Taiwan, ROC) (20’)

30P. CYTOGENETICS AND GENETICS (POSTERS)

  • The combinative effects of DNA APEX1 genotype and smoking habits on Taiwan lung cancer risk. S.-S. Chien, W.-S. Chang, S.-C. Wang, C.-Y. Huang, Y.-L. Hsiao, C.-H. Liao, C.-H. Loh, C.-E. Miao, L.-L. Hou, N.-C. Shieh, C.-W. Tsai, C.-M. Hsu, D.-T. Bau (Taichung; Taipei, Taiwan, ROC)
  • Novel non-hot spot APC mutations in Familial Adenomatous Polyposis (FAP) in Thai Families. A. Tunteeratum, C. Kunasol, M. Busabaratana, K. Srichan, T. Sura (Bangkok, Thailand)
  • Germline mutation of MLH1, MSH2 in young-onset nonpolyposis colorectal cancer: Two novel mutations in Thai families. A. Tunteeratum, C. Kunasol, J. Eu-ahsunthornwattana, M. Busabaratana, K. Srichan, T. Sura(Bangkok, Thailand)
  • EGFR mutations in greek patients with lung adenocarcinoma: a multi-center study. A. Kallianos, H.Kerasiotis, P.Zarogoulidis, K. Marosis, F. Vlastos, I. Veldekis, M. Aggelidou, K. Zarogoulidis, A. Rapti (Thessaloniki, Greece)
  • Host polymorphisms and virulence genotypes of Helicobacter pylori as risk factors for gastric cancer. P. Gonzalez-Hormazabal, M. Musleh, M. Bustamante, J. Stambuk, S. Escandar, H. Valladares, E. Lanzarini, M. Meneses, J. Wettlin, H.Chiong, J. Rojas, V. Gonzalo Castro, L. Jara, Z. Berger (Santiago, Chile)

31. CARCINOGENESIS

ROOM C, 15.45-19.10 – Tuesday, October 7

Chair Persons: G.R. Rutteman, H.C.R. Wang

  • Reactive oxygen species-mediated breast cell carcinogenesis enhanced by chronic exposure to multiple carcinogens and intervened by dietary agents. H.C.R. Wang, L.A. Pluchino (Knoxville, Tennessee, USA) (40’)
  • Helicobacter pylori: Multitalented adaptation of binding properties. T. Borén (Umea, Sweden) (40’)
  • Molecular biological and genetic investigations of cancers in companion animals can provide important insight in (rare) cancers in the human. G.R. Rutteman (Utrecht; Wageningen, The Netherlands) (30’)
  • The role of the ECL cell in gastric carcinogenesis. H.L. Waldum, Ø. Hauso, Ø. Sørdal, R. Fossmark (Trondheim, Norway)(20’)
  • A preliminary mutagenesis study of camphor in human leukocytes culture. J.C. Santos, M.F. Bellini (Bauru, Brazil) (30’)
  • Silver nanoparticles increase the ionic permeability of the pleura and partially inhibit the migration of pleural mesothelial cells. V. Arsenopoulou, P.A. Molyvdas, K. Gourgoulianis, C. Hatzoglou, S.G. Zarogiannis (Larissa, Greece) (10’)

31P. CARCINOGENESIS (POSTERS)

  • The role of splicing factor expression on the latent/lytic switch during replication of oncogenic Kaposi Sarcoma herpesvirus. S. Laurinavicius, I. Kunigenas, E. Kulvietyte, E. Strainiene, K. Sužiedelis (Vilnius, Lithuania)
  • Canine transmissible venereal tumor in relation with breed, age, sex, anatomic location and year of presentation. A. Agüero, B. Álvarez, A. Amaya, A. Alvarado (Barquisimeto, Lara. Venezuela; Vila Real, Portugal)
  • Chemopreventive effects of cyclooxygenase-2 inhibitors against 1,2-dimethyl hydrazine (dmh)-induced rat colon carcinogenesis. H. Gungor, N. Ilhan, H. Eroksuz, I.H. Ozercan (Elazig, Turkey)

32. MICROENVIROMENTAL HETEROGENEITY OF BRAIN TUMOURS: DYNAMIC TOPOGRAPHICAL CHANGES AND ADAPTATION TO THERAPIES
Special Symposium Organized by G. Pilkington and H. Fillmore

ROOM D, 8.00-15.30 – Tuesday, October 7

Chair Persons: C. Herold-Mende, H. Fillmore, G. Pilkington

  • Introduction
  • Urban and rural communities, transport modalities, differing cultures and climate change – The admixture which defines the brain tumour micro-environment. G. Pilkington (Portsmouth, UK) (30’)

Part 1. Microenvironmental drivers of glioma heterogenecity and therapeutic resistance: Antiogenesis
Chair Person: C. Herold-Mende

  • Adaptive mechanisms to anti-vascular therapy. R. Bjerkvig (Bergen, Norway) (30’)
  • The perivascular glioma niche and its role in therapeutic resistance: safe harbour or active participant? H. Fillmore (Portsmouth, UK) (30’)

Part 2: Microenvironmental drivers of therapeutic resistance: Immune-mediated resistance
Chair Person: H. Fillmore

  • Contribution of the immunological microenvironment on GBM survival. C. Herold-Mende (Heidelberg, Germany)(30’)
  • Mesenchymal stem cells affect glioblastoma cells upon direct contact. H. Motaln, J. Schuchhard, K. Stec, B. Breznik, H. Ulrich, T.T. Lah (Sao Paulo, Brazil; Ljublijana, Slovenia) (30’)
  • Paradoxical role of mesenchymal stem cells in glioblastomas microenvironment. H. Motaln, J. Schuchhardt, K. Stec, B. Breznik, H. Ulrich and T.T. Lah (Potsdam; Berlin, Germany; Sao Paulo, SP, Brazil; Ljublijana, Slovenia) (20’)

Part 3. Post-doctoral and student presentations (10 min + 5 min discussion)
Chair Person: G. Pilkington

  • T cell target repertoire in primary and recurrent glioblastomas. C. Rapp, R. Warta, S. Stamova, P. Beckhove, M. Schnölzer, C. Herold-Mende (Heidelberg, Germany) (10’)
  • Mitochondrial DNA mutations and brain tumour heterogeneity: Insights from three dimensional structural analysis. K. Keatley, R.E Lloyd, Q. An, H.L. Fillmore, G. J. Pilkington, J.E. McGeehan (Portsmouth, UK) (10’)
  • CD15 and E-selectin mediate adhesion of non-small cell lung cancer cells to brain endothelium. S.A. Jassam, Z. Maherally, J. Smith, K. Ashkan, H.L. Fillmore and G.J. Pilkington (Portsmouth, UK) (10’)
  • Trick or treat: Impact of the microenvironment on the infiltration of T-cells in lower grade gliomas. S. Dettling, A. Moch, C. Geinsenberger, L. Hartmann L, A. von Deimling A, C. Herold-Mende (Heidelberg, Germany) (10’)
  • Deacetylation of GD3A as a potential therapeutic strategy for paediatric medulloblastoma. R. Mather, K. Stephenson, H.L. Fillmore, G.J. Pilkington (Portsmouth, UK) (10’)

Part 4. Microenvironmental impact on the cross-talk between glioma cells, immune cells and antiogenesis in glioblastoma: Potential combinational targets (Round table discussion)
Chair persons: H. Fillmore, C. Herold-Mende, R. Bjerkvig , G. Pilkington

  • Experimental questions/design to explore potential micro-environmental therapeutic targets; Challenges and EU collaborative proposals (ie. COST)

33. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM D, 15.45-19.10 – Tuesday, October 7

Chair persons: F. Guadagni, K. Hellstrand, J. Koch

  • Natural killer cell expression ofnatural cytotoxicity receptors determines relapse risk in elderly patients with acute myeloid leukemia undergoing immunotherapy with histamine dihydrochloride and interleukin-2. A. Martner, A. Rydström, R.E. Riise, J. Aurelius, M. Brune, R. Foà, K. Hellstrand, F.B. Thorén (Rome, Italy) (20′)
  • Histamine promotes the differentiation of dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase. A. Martner, B. Lenox, H. Grauers Wiktorin, J. Aurelius, F. Ewald, E. Aydin, F.B. Thorén, S. Hermodsson, K. Hellstrand (Gothenburg, Sweden) (30’)
  • The SR/CR mouse model of cancer resistance. J. Koch (Copenhagen,Denmark) (20’)
  • Unique activated state of U937 derived macrophage. H. Ishii, M. Ishikawa, T. Inoue, Y. Sumiya, Y. Kobayashi, H. Kouda, T. Gotoh, S. Kasutani, T. Inui, D. Kuchiike, K. Kubo, Y. Uto, T. Nishikata (Kobe; Tokushima; Osaka, Japan) (15’)
  • Establishment and comparison of novel assay systems for activation of macrophage using two different types of human monocytic cell line. M. Ishikawa, H. Kouda, T. Inoue, T. Inui, D. Kuchiike, K. Kubo, Y. Uto, T. Nishikata (Kobe; Tokushima; Osaka, Japan) (15’)
  • Interaction of uterine tumors with the immune system: implications for immunotherapy. S. Tuyaerts, A. Vanderstraeten, T. Everaert, R. Van Bree, C. Luyten, G. Verbist, F. Amant (Leuven, Belgium) (30’)
  • Vaccination with WT1 mRNA-electroporated dendritic cells to prevent relapse in 30 acute myeloid leukemia patients. E.L. Smits , A. Van de Velde, S. Anguille, Y. Willemen, W.A. Schroyens, A.P. Gadisseur, A. Verlinden, I. Vrelust, M. Lammens, G. Nijs, B. Stein, N. Cools, R. Malfait, M.B. Maes, K. Vermeulen, V.F. Van Tendeloo, Z.N. Berneman (Antwerp, Belgium) (30’)
  • Critical role of Toll-like receptors and regulatory T-cells during Helicobacter pylori-induced immunity and gastric carcinogenesis. C. Prinz, K. Kakounis, R. Mejías-Luque, R. Käbisch and M. Gerhard (Witten; Munich, Germany) (30’)

33P. IMMUNOTHERAPY; BIOTHERAPY; VACCINES. (POSTERS)

  • Clinical experience of immunotherapy based on oleic acid bound to glycosylated vitamin D-binding protein in localised and metastatic adenocarcinoma of the pancreas. L. Thyer, J.J.V. Branca, M. Taubmann (Cambridge, UK; Firenze, Italy; Bayreuth, Germany)
  • Bioluminescence analysis of adoptively transferred t lymphocytes during allogeneic tumor rejection. J. Juršenaite, D. Characiejus (Vilnius, Lithuania)
  • Association of p53 expression with s-100 and hla-dr positive cells in colorectal cancer patients. M. Gulubova, I. Vasilev, K. Ivanova, J. Ananiev, M.M. Ignatova, T. Vlaykova (Stara Zagora, Bulgaria)

34. CHEMOPREVENTION. ENVIRONMENTAL EXPOSURE AND CANCER RISK

ROOM E, 8.00-12.00 – Tuesday, October 7

Chair Persons: W. Weber, B. Davidson

  • Familial cancer and prevention. W. Weber (Basel, Switzerland) (20’)
  • A review of risk factors in urothelial cancer. D. Curry, M. Ruddock, S. Dalleau, G. Kennedy, B. Duggan, H. O’Kane, C. Reid, K. Williamson (Belfast, UK) (20’)
  • Molecular backgrounds of chemoprevention: selenite, phenolics, chalcones. P. Perjési (Pecs, Hungary) (20’)
  • The incidence of cancer mortality in the Caribbean region from 2006 to 2012. B. Davidson (Anguilla, British West Indies) (20’)
  • Carotenoids and their derivatives prevent cancer by affecting the activity of diverse transcription systems. J. Levy (Beer-Sheva, Israel) (20’)
  • Plant-derived micronutrients inhibit estrogenic and IGF-1 activity in breast cancer cells but not in bone cells. Y. Sharoni (Beer Sheva, Israel) (20’)

35. BREAST CANCER: PATHOLOGY AND IMAGING
Special Symposium Organized by N.J. Agnantis

ROOM E, 13.00-15.00 – Tuesday, October 7

Chair Persons: N.J. Agnantis
Round Table

  • Pathogenesis of mammary microcalcifications. A. Batistatou (Ioannina, Greece) (20’)
  • Breast calcifications: Imaging. A. Vourtsi (Athens, Greece) (20’)
  • Vacuum-assisted biopsy (VAB) and pathology. A. Nonni (Athens, Greece) (20’)
  • The role of Surgeon in microcalcifications of the breast. I. Karydas (Athens, Greece) (20’)

Discussion(10’)

  • Columnar cell lesions of the breast. A.C. Goussia (Ioannina, Greece) (30’)

36. CANCER STEM CELLS
Special Symposium Organized by M. Jhanwar-Uniyal, G. Sica

ROOM E, 15.15-19.00 – Tuesday, October 7

Chair Persons: G. Sica, M. Jhanwar-Uniyal

  • Cancer stem cells: secret and promises. G. Sica (Rome, Italy) (30’)
  • Mesenchymal stromal/ stem cells (MSCs) and cancer stem cells (CSCs), a tangled interrelationship with intriguing pathophysiological and clinical implications. R. Scatena, P. Bottoni, F. Iacopino, G. Sica(Rome, Italy) (40’)
  • Characterization of signaling pathways associated with cancer stem cells of glioblastoma multiforme. M. Jhanwar-Uniyal (New York, NY, USA) (30’)
  • A new way to think about tumor stem cells. J.A. Radosevich, B.T. Murphy, X. Wei, K.M. Elseth, Z.Deliu, M.Aqil, M. Bassiony (Chicago, IL, USA) (20’)
  • Alterations in DNA topoisomerases activity in cancer stem cells and in bacterial infected tumor cells influence the efficacy of anti-cancer agents. E. Priel, R. Peleg, R.Afriat, Y. Mizrachi-Nebentzahl, S. Horowitz (Beer-Sheva, Israel) (30’)
  • Proteome-based personalized anti-tumor cell therapy. A.S.Bryukhovetskiy, I.S. Bryukhovetskiy (Moscow, Russian Federation) (15’)

37. NEW INSIGHTS IN RENAL CANCER
Special Symposium of SIUrO Organized by G. Sica and G. Conti

ROOM F, 8.00-14.00 – Tuesday, October 7

Chair Persons: G. Sica, G. Martorana
Welcome address by Giario Conti, SIUrO President

  • Precision medicine in renal cancer: Biomarker and genomic profile studies. G.L. Pappagallo (Venice, Italy) (30’)
  • Genomics in translational research and targeted therapies in Renal Cancer. S.C. Jhanwar (New York, NY, USA) (30’)
  • Toward a new histo-pathological classification of renal tumours. G. Martignoni, D. Segala (Verona, Italy) (30’)
  • New methods in evaluation of VHL gene. E. Bollito, S. Vatrano, S. Cappia (Turin, Italy) (30’)
  • Radical nephrectomy versus partial nephrectomy in localized renal cell carcinoma. G. Martorana (Bologna, Italy) (30’)
  • Renal biopsy, mininvasive techniques and active surveillance in small renal tumors. A. Lapini (Florence, Italy) (30’)
  • The role of surgery in locally advanced or metastatic renal cell carcinoma (rcc). R. Salvioni (Milan, Italy) (30’)
  • First line medical therapy in advanced metastatic RCC. C. Porta, P. Giglione, F. Lombardo, C. Paglino (Pavia, Italy) (20’)

Conclusion : G. Conti


38. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM F, 14.15-16.15 – Tuesday, October 7

Chair Person: L. Amaral, G. Giamas

  • ATP-binding cassette (ABC) transporters are still important drug targets for combating multidrug-resistant cancer cells. G. Sgaragli (Siena, Italy) (30’)
  • Platinum (IV)nitroxyl complexes as possible candidates to circumvent cisplatin resistance in bladder cancer cells. M. Cetraz, V. Sen, A. Hartwig, B. Köberle, (Karlsruhe, Germany) (25’)
  • Nitric oxide donor-doxorubicins as MDR reversing agents. E. Gazzano, K. Chegaev, I. Pedrini , J. Kopecka, B. Rolando, R. Fruttero, S. Arpicco, D. Ghigo, C. Riganti (Torino, Italy) (20’)
  • Mitochondrial-targeting nitrooxy-doxorubicin: effects on P-glycoprotein and assessment of their vascular effects. M. Frosini, V. Maestrini, A. Neri, C. Santulli, C. Brizi, K. Chegaev, C. Riganti, G. Sgaragli, N.A. Colabufo, S. Saponara (Siena; Torino; Bari, Italy) (10’)
  • Screening for potential hazard effects from multitarget anthracycline on cardiovascular system. S. Saponara, M. Durante, M. Frosini, B. Gorelli, M. Valoti, K. Chegaev, G. Sgaragli, F. Fusi F (Siena; Torino, Italy) (10’)

38P. MULTI-DRUG AND DRUG RESISTANCE. MECHANISMS AND REVERSAL (POSTERS)

  • Chemosensitizing effects of low molecular weight heparin on cisplatin-resistant ovarian cancer cells. D. Pfankuchen, D.P. Stölting, G. Bendas (Bonn, Germany)
  • How liposomal cisplatin overcomes chemoresistance in ovarian tumour cells. B.P. Stölting, M. Borrmann, M. Koch, M. Wiese, H.-D. Royer, G. Bendas (Bonn; Stuttgart; Duesseldorf, Germany)
  • Expression of chemoresistance markers in glioblastoma (GBM) and in peritumoral tissue. F. Iacopino, S. Sorrentino, G. Proietti , F. Biamonte, A. Mangiola, G. Maira, G. Sica (Rome, Italy)
  • Multidrug resistance reversal by phenothiazines on p glycoprotein related resistance of colon adenocarcinoma cells. A.M. Szabó, G. Spengler, D. Takács, Z.S. Riedl, G.Y. Hajós, L. Amaral, J. Molnár (Szeged; Budapest, Hungary; Lisbon, Portugal)
  • The modulations of DNA repair induced by DNA damaging agents used in cancer therapy by carb pharmacophores. A. Macieja, A. Czubatka, J. Sarnik, Z.J. Witczak, T. Poplawski (Lodz, Poland; Wilkes-Barre, PA, USA)
  • HSPA2 chaperone protein modulates sensitivity of non-small cell lung carcinoma cells to cisplatin. D. Scieglinska, A. Habryka, P. Filipczak, A. Gogler-Piglowska, D. Sojka, U. Bojko, Z. Krawczyk (Gliwice, Poland)

39. NEW ANTICANCER AGENTS

ROOM F, 16.30-19.30 – Tuesday, October 7

Chair Persons: A. Bhushan, H.M. Warenius

  • Tyrosine phosphorylation: Role in antifolate resistance. A. Bhushan, T. Liu, P. Sheridan and J.C.K. Lai (Philadelphia, PA, USA) (30’)
  • Global anticancer targets: still a possibility? H.M. Warenius (Southampton, UK) (30’)
  • Brk/PTK6 as a novel therapeutic target in breast cancer. R.S. Burmi, G.A. Box, C.J. Pennington, J.A. Davies, W.J. Court, S.A. Eccles, D.R. Edwards, A. Harvey (Uxbridge, UK) (30’)
  • Identification and design of new C5-DNA methyltransferase inhibitors and their biological activity. P.B. Arimondo (Toulouse, France) (30’)
  • Exploiting the potential of lipids and frogs foams to treat Cancer. D.A. Lamprou (Glasgow, Scotland, UK) (20’)
  • Initial evaluation of a CD146/MUC18 targeting radioimmunoconjugate. S. Westrøm, N. Abbas, R.H. Larsen, O.S. Bruland, T.J. Jonasdottir, T.B. Bønsdorff (Oslo, Norway) (10’)

39P. NEW ANTICANCER AGENTS (POSTERS)

  • Cyclic chalcone analogues as new potential anticancer agents. P. Perjési (Pecs, Hungary)
  • Activated-CD44 plays a crucial role in selective targeting to breast cancer. C. Yang, M. Cao, H. Zhang, Y. Liu, Y. He, W. Wang, Y. Du, F. Gao (Shanghai, China PR)
  • Physical – chemical analysis of Lippia alba and Melissa officinalis and clastogenicity evaluation of its aqueous extracts in human leukocytes. T.B. Queiroz, J.C. Santos, F.T.A. Neves, M.F. Bellini (Bauru, Brazil)
  • Metal-induced modulation of nitric oxide and singlet oxygen production by light irradiation. Physical chemistry characterizations and cytotoxicity studies. L.C.B. Ramos, J.A. Uzuelli, F.B. Do Nascimento, A.O. Ribeiro, J.C.B. Moraes, R.S. da Silva, (Ribeirão Preto; Santo André, SP, Brazil)
  • Lipophilic cations gallic acid derivatives exert mitochondrial toxicity and induce apoptosis genes expression detected by real time RT-PCR. L. Peredo, K. Cortés, J.A. Jara, V. Castro-Castillo, J. Saavedra-Olavarría, M. Pavani, J. Ferreira (Santiago, Chile)
  • Effects of Ketotifen on mammry tumors volume and weight. A.I. Faustino-Rocha, C. Pinto, A. Gama, P.A. Oliveira (Vila Real, Portugal)
  • Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells. E. Pastwa, T. Poplawski, B. Somiari, J. Blasiak and R.I. Somiari (Lodz, Poland; Windber, PA, USA; Johnstown, PA, USA)

Wednesday, October 8


40. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-16.45 – Wednesday, October 8

Chair Persons: B. Kaina, M.M. Müller

  • Establishment of a standardized 3D in vitro tumor-stroma model. S. Hensler, B. Kotkamp, K.I. Pohl, N. Linde, D. Stoll, M.M. Müller (Furtwangen; Sigmaringen; Reutlingen, Germany; New York, NY, USA) (30’)
  • Production of Urocortin 1 in human malignant cell lines. Y. Manome, K. Fujioka, T. Tachibana, K. Tojo, K. Ikeda (Tokyo, Japan) (10’)
  • The oncogenic potential of ribonucleotide reductase M2 (RRM2) in clear cell renal cell carcinoma. M. Abudawood, N. Ahmed, Q. Wang (Manchester, UK) (30’)
  • Stem cell-based therapy: A double-edged sword? Z.Y. Abdel-Magee, Y. Yang, R. Thomas,M. Ranjan, D. Mondal, K. Moroz, B. Rezk, K.Moparty, A.B. Abdel-Mageed (New Orleans, LO, USA) (15’)
  • Expression of CRABP proteins in different types of human cancer. E. Tchevkina, Y. Kainov, I. Favorskaya, V. Delektorskaya, G. Chemeris, A. Komelkov, A. Zhuravskaya, I. Zborovskaya (Moscow, Russia) (20’)

Chair Persons: T. Isbir, Q. Wang

  • Mechanism of inhibition of thymidylate synthase-catalyzed reaction by N4-OH-DCMP in view of crystallographic studies. W. Rode, A. Dowiercial, P. Wilk, A. Jarmula, K. Krawiec, W. Rypniewski, B. Kierdaszuk (Warsaw, Poland) (30’)
  • STAT3 and sphingosine-1-phosphate signaling in inflammation associated colorectal cancer. A.V. Nguyen, Y.-Y. Wu, E. Lin (Bayside, NY, USA) (30’)
  • Emerging roles of bioactive sphingoids in glioblastoma aggressiveness . G. Marfia, C. Di Vito, L. Abdel Hadi, S. Navone, R. Campanella, L. Riboni (Milan, Italy) (20’)
  • Prediction of Heat-Shock Proteins from Sequence Information. A. Jerrison, S. Seker, C. Chrysostomou, A.B. Dalan, T. Isbir (Leicester, UK; Istanbul, Turkey) (10’)

Chair Persons: F.L. Queiroga, J. Schneider

  • New Insights into Cox-2 pathways in cancer: the dog as a promising model. F.L. Queiroga, M.I. Carvalho, T. Raposo, J. Prada, H. Gregório, I. Pires (Vila Real, Portugal) (30’)
  • Mutational analysis of the APC gene in FAP-associated desmoid tumors. M.L. De Marchis, R. Palmirotta, L. Picariello, D. Della-Morte, P. Ferroni, M. Roselli, F. Tonelli, F. Guadagni (Rome; Florence, Italy) (20’)
  • The interplay between CD3+ T-lymphocytes and concurrent COX-2/EGFR expression in canine malignant mammary tumours. M.I. Carvalho, I. Pires, J. Prada, F.L. Queiroga(Braga, Portugal) (30’)
  • Thermodynamic differences between cancer and normal cells. J. Molnár, B.S. Thornton (Szeged, Hungary; Sydney, Australia) (30’)
  • Degarelix activity on cell growth and cell migration of three human prostate cancer cell lines. F. Iacopino, S. Sorrentino, G. Sica (Rome, Italy) (15’)
  • Novel telomerase activators in aging and age related diseases. E. Priel, E. Eitan, A. Tichon, I. Levi, R. Peleg, A. Gazit, S. Slavin (Beer-Sheva; Tel-Aviv, Israel) (20’)
  • Tryptophan metabolism, neopterin and cancer. J.M. Gostner, K. Becker, F. Ueberall, D. Fuchs (Innsbruck, Austria) (20’)
  • Possible contribution of BRAFV600E mutation to TGF- ß1/ NFIC dependent aberrant methylation pattern in colorectal cancer. P. Karpinski, N. Blin, M.M Sasiadek (Wroclaw, Poland) (15’)
  • Lung cancer incidence and survival in association to expression of anti- and pro-apoptotic proteins in chromium exposed individuals. E. Halasova, T. Matakova, T. Dzian, S. Javorkova, K. Javorka, D. Dobrota (Martin; Ružomberok, SlovakRepublic) (10’)
  • Osmotic stress alters the permeability of the pleura and the migration properties of mesothelial cells. V. Peppa, E. Solenov, I. Tsilioni, I. Kalomenidis, P.A.Molyvdas, K. Gourgoulianis, C. Hatzoglou, S.G. Zarogiannis (Larissa; Athens, Greece; Novosibirsk, Russia) (10’)

40P. MOLECULAR AND CELLULAR BIOLOGY OF CANCER (POSTERS)

  • Translational regulation of HB-EGF mRNA via a translational regulator, RBM8A. K. Miyata, F. Yotsumoto, S. Ouk Nam, S. Fukagawa, M. Kuroki, S.Miyamoto (Fukuoka, Japan)
  • Head and neck cancer cell lines adapted to high nitricoxide (HNO) levels consistantly up-regulate lipocalin 2 (LCN2). Z. Deliu, M.D. Rojas, K. Elseth, M. Aqil, M.Bassiony, B. Vesper, J.A. Radosevich (Chicago, IL, USA)
  • Effect of blood leukocytes and PBMCs isolated from tumor-bearing and healthy rats on D6 rat sarcoma cells in vitro. R. Mishra, V. Horak, J. Janda, R. Rajmon (Libechov; Prague, Czech Republic)
  • Risk of lung cancer development in association with mismatch repair gene polymorphisms. E. Halasova, P. Slovakova, T. Matákova, M. Halasa, T. Dzian, S. Javorkova, K. Javorka, L. Musak(Martin; Ružomberok, Slovak Republic)
  • Prognostic value of EGF and p53 genetic changes in colorectal cancer in the Slovak population. T. Matakova, S. Mahmood, E. Halasova, A. Dzian, M. Halasa, L. Wsolova, D. Dobrota (Martin; Ružomberok, Slovak Republic)
  • In vitro analysis of redox status of normal and tumor cells using nitroxide radicals and electron paramagnetic resonance spectroscopy. E. Georgieva, D. Ivanova, D. Lazarova, R. Bakalova, I. Aoki, Z. Zhelev (Stara Zagora; Sofia, Bulgaria; Chiba, Japan)
  • Epithelial Mesenchymal Transition (EMT) in non-small cell lung cancers. N. Tsoukalas, C. Giaginis, S. Siakavellas, I. Kostakis, M.Tolia, M.Kiakou, E. Bournakis, A. Papakostidi, I. Sfiniadakis, A. Karameris, S. Theocharis (Athens, Greece)

41. CYTOGENETICS AND GENETICS

ROOM A, 17.00-19.30 – Wednesday, October 8

Chair Persons: W. Weber, I. Kiss

  • Familial cancer: The alert clinician and UICC. W. Weber (Basel, Switzerland) (15’)
  • Role of allelic polymorphisms in the susceptibility to colorectal and head- and neck cancers. I. Kiss, Z.S. Orsós, J. Cseh, A.Csejtei, I. Szanyi, G. Pajkos, A. Németh (Pecs; Székesfehérvár; Szombathely; Kecskemét, Hungary) (20’)
  • Association between ERCC2 gene polymorphism and primary ovarian cancer. G. Yildirim, R. Attar, C. Fiçicioglu, Gulec-Yilmaz, Ö Timirci-Kahraman, H. Atasoy , Ö Kizilkale-Yildirim, C. Iyibozkurt, A. Buyukoren, A.B. Dalan, B. Çakmakoglu, A. Ergen, T. Isbir (Istanbul, Turkey) (20’)
  • Etiological observations in 7 patients with pancreatic neuroendocrine tumors (PNETs). W. Weber (Basel, Switzerland) (15’)
  • RRM1 and RRM2 gene polymorphisms in patients with primary ovarian cancer. R. Attar, G. Yildirim, C. Fiçicioglu, S. Gulec-Yilmaz, Ö Timirci-Kahraman, H. Atasoy, Ö Kizilkale-Yildirim, C. Iyibozkurt, A. Buyukoren, A.B. Dalan, I. Yaylim, U. Görmüs,T. Isbir (Istanbul, Turkey) (20’)
  • Silent mutation in HLA-E gene is associated with Tunisian nasopharyngeal cancer. H. Douik, N.A. Romdhane, C. Fortier, M. Makni, L. Harzallah, R. Khrishnammorthy, D. Charron, R. Tamouza, F. Guemira (Tunis, Tunisie; Paris, France) (15’)
  • Relationship of genetic polymorphism of transforming growth factor-beta1 (TGF-ß1) with urinary bladder cancer – a cases-control study on North Indian population. Kirti, S.N. Sankhwar, R. Singh, P.L. Sankhwar, A. Goel, D. Dalela (Lucknow, Uttar Pradesh, India) (10’)

41P. CYTOGENETICS AND GENETICS (POSTERS)

  • Analysis of breast and ovarian cancer related gene mutations in Canadian and Saudi Arabian breast cancer patients. Y. Amemiya, S. Bacopulos, E. Slodkowska, M. Al-Shawarby, D. Al-Tamimi, W. Naser, M. Khalifa, A. Seth (Toronto, ON, Canada; Dammam, Saudi Arabia)
  • The trail C1595T polymorphism are potential genetic marker of susceptibility to bladder cancer: a case-control study. O. Timirci-Kahraman, I.Yaylim, S.Turan, N.E. Ozkan, L. Verim, T.Ozturk, C. Cakalir, E.N. Yenilmez, G.I. Gultekin, T.Isbir (Istanbul, Turkey)
  • Possible role of IL6 -174G>C promoter polymorphism in cutaneous malignant melanoma – preliminary study. T. Vlaykova, M. Kurzawski, D. Dimov, M. Gulubova, M. Drozdzik (Stara Zagora, Bulgaria; Szczecin, Poland)
  • A missense mutation C.440G>A (ARG147HIS) in STK11 gene found in Bulgarian patient with sporadic breast cancer. G.G. Antov, P. Kleiblova, M.E. Krasteva, S.G. Angelova, D.I. Toncheva (Sofia, Bulgaria; Prague, Czech Republic)

42. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM B, 8.00-12.00 – Wednesday, October 8

Chair Persons: L. Amaral, J. Molnar

  • Similar responses of MDR cancer and bacteria to the same inhibitor of efflux pumps in general. L. Amaral, J. Molnar (Lisbon, Portugal; Szeged, Hungary) (20’)
  • Heat-shock protein HSP27 in anticancer mechanisms. M.B. Stope, U. Zimmermann, R. Walther, M. Burchardt (Griefswald, Germany) (25’)
  • Plant-derived compounds for modulating pgp-mediated mdr in cancer cells. M.-J.U. Ferreira (Lisbon,Portugal) (30’)
  • Antitumour effects of selected plant polyphenols, gallic acid and ellagic acid, on sensitive and multidrug resistant leukaemia HL60 cells. A. Maruszewska, J. Tarasiuk (Szczecin, Poland) (30’)
  • P-glycoprotein expression is downregulated by temozolomide in glioblastoma stem cells. I.C. Salaroglio, V. Caldera, I. Campia, J. Kopecka, M. Mellai, L. Annovazzi, A. Bosia, D. Ghigo, D. Schiffer, C. Riganti (Turin; Vercelli, Italy) (10’)
  • Edysteroids potentiate the activity of doxorubicin in cancer. A. Martins, J. Csabi, J. Molnár, L. Amaral, A. Hunyadi (Szeged, Hungary; Lisbon, Portugal) (15’)
  • Multidrug resistance reversing activity of newly developed phenothiazines on p glycoprotein (ABCB1)-related resistance in different cancer models. G. Spengler, D. Takács, Z. Riedl, G. Hajós, L. Amaral, J. Molnár (Szeged; Budapest, Hungary; Lisbon, Portugal) (15’)
  • Semi- and total-synthetic protoflavone derivatives as MDR selective anticancer agents. B. Dankó, A. Martins, L. Amaral, J. Molnár, M. Pešic, G. Szakács, A. Hunyadi (Szeged; Budapest, Hungary; Lisbon, Portugal; Belgrade, Serbia) (15’)
  • SILAC-based analysis reveals a unique phosphoproteomic-signature of HER2-resistant breast cancer cells. J.F.G. Nunes, H. Zhang, J. Stebbing, N. Angelopoulos, G. Giamas (London, UK) (15’)
  • Effects of ABCE1 downregulation by RNAi on chemosensitivity of lung cancer cells. G. Kara, S. Tuncer, M. Turk, E.M. Denkbas (Beytepe, Ankara; Yahsihan, Kirikkale, Turkey) (15’)

42P. MULTI-DRUG AND DRUG RESISTANCE. MECHANISMS AND REVERSAL (POSTERS)

  • Overcoming drug resistance using a nanoparticulate form of a polymeric p-glycoprotein inhibitor with ultrasound. J. Jackson, K. Letchford, D. Leung, L. Wan and H. Burt (Vancouver, Canada)
  • Comparison of cytotoxicity of butyl-oxi-carbonyl substituted steroidal compounds on different cancer cell lines in vitro. A. Csonka, G. Spengler, A. Martins, I. Vincze and J. Molnar (Szeged, Hungary; Lisbon, Portugal)
  • Significance of ERK subcellular localization in cisplatin resistance of ovarian cancer cells. S. Dilruba, M. Michaelis, Cinatl Jr. J, N.T. Ueno, A.C. Schiedel, G.V. Kalayda (Bonn; Frankfurt/Main, Germany; Canterbury, UK; Houston, TX, USA)
  • New pharmacological tools against chemoresistant osteosarcoma. I. Buondonno, E. Gazzano, J. Kopecka, D. Ghigo, C. Riganti (Torino, Italy)
  • Effect of reductive activation of antitumour anthracycline drugs by NADPH cytochrome P450 reductase on their intracellular accumulation in sensitive LoVo and multidrug resistant LoVo/Dx colon cancer cells. R. Nowak, W. Zwierello, D. Kostrzewa-Nowak, J. Tarasiuk (Szczecin, Poland)
  • Identification of ALDH1A1 positive cancer stem like cells in drug resistance ovarian cancer cell lines. R. Januchowski, K. Wojtowicz, T. Wysocka, M. Zabel (Poznan; Wroclaw, Poland)
  • New analog of sulforaphane – ITC 2-oxoheptyl reduce the MDR phenomenon – study on normal and colon cancer cells. K. Lubelska, K. Wiktorska, M. Milczarek, L. Sliwka, Z. Chilmonczyk (Warsaw; Lublin, Poland)
  • SNPS 72ARG/PRO OF p53 AND 344 T/A OF MDM2 are not associated with chemoresistance of breast cancer in Tunisia. A. Arfaoui, H. Douik, G. Kablouti, N. Handiri, Z. Zid, N. Ouni, F. Zouiouiche, F. Ayari, T. Mamoghli, A. Ben Chaabene, J. Bouassida, H. Abazza, L. Harzallah and F. Guemira (Tunis,Tunisia)

43. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM B, 13.00-16.00 – Wednesday, October 8

Chair Persons: P. Ferroni, C. Sansom, G. Karanikas

  • Fluorodeoxyglucose uptake in advanced non-small cell lung cancer with and without pulmonary lymphangitic carcinomatosis. H. Ooi, C.Y. Chen, Y.C. Hsiao, W.S. Huang, B.T. Hsieh (Taichung, Taiwan) (40’)
  • Expression of antigen processing machinery components in tonsillar (TSCC) and Base Of Tongue Cancer (BOTSCC) in relation to Human Papillomavirus (HPV) and clinical outcome. T. Ramqvist, N. Tertipis, L. Haeggblom, C. Nordfors, N. Grün, A. Näsman, A. Vlastos, T. Dalianis (Stockholm, Sweden) (15’)
  • Clinical value of scintimammography in diagnosis, treatment monitoring and follow- up. M.R. El-Zahry, M. Rodrigues-Radischat, P. Berghammer, H. Sinzinger (Vienna, Austria) (25’)
  • New predictors of venous thromboembolism in ambulatory cancer patients. P. Ferroni (Rome, Italy) (30’)
  • Evaluation of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) in detection of suspected extra adrenal paraganglioma. G. Karanikas, K. El-Rabadi, A. Khameneh, M. Weber, M. Mayerhoefer, M. Hacker (Vienna, Austria) (10’)
  • MicroRNAs in cerebrospinal fluid – potential diagnostic tools for CNS lymphomas. M. Chechlinska, M. Zajdel, G. Rymkiewicz, M. Cieslikowska, K. Blachnio, Z. Bystydzienski , K. Goryca, A. Druzd-Sitek, M. Sromek, J. Walewski, J.K. Siwicki (Warsaw, Poland) (10’)
  • Correlation of RCAS1 and CD3 expression and their clinical significance in non-small cell lung cancers. N. Tsoukalas, C. Giaginis, S. Siakavellas, I. Kostakis, M. Tolia, M. Kiakou, E. Bournakis, A. Papakostidi, I. Sfiniadakis, A. Karameris, S. Theocharis (Athens, Greece) (10’)

43P. DIAGNOSIS AND PROGNOSIS OF CANCER (POSTERS)

  • The significance of histopathological evaluation of pancreatic fibrosis to estimate pancreas cancer progression. S. Osada, K. Tanaka, S. Matsui, H. Imai, Y. Sasaki, H. Tomita, Y. Tanaka, H. Matsuhashi, K. Yoshida (Gifu, Japan)
  • Characterization of canine lymphoma by cytological study according to human classification of Kiel and its association with age, sex and breed. A. Alvarado, V. Balza, V. Colmenarez, Y. Salas, A. Corro (Barquisimeto, Lara, Venezuela; Vila Real, Portugal)
  • Primary tumors of the duodenum: Experience of a single center. A. Scarlat, C. Stroescu, O. Bouaru, V. Herlea, C. Pechianu, M. Ionescu,I. Popescu (Bucarest, Romania)
  • Ki67 proliferative index in gastric cancer: A useful prognostic marker? H. Amrani Hassani Joutei, N. Marchoudi, I. Sadaoui, W. Mahfoud, F. Haddad, T. Fechtali and H. Benomar (Casablanca ; Mohammedia, Maroc)
  • Epidemiological aspects of gastric adenocarcinoma in Morocco. H. Amrani Hassani Joutei, N. Marchoudi, W. Mahfoud, I. Sadaoui, F. Haddad, T. Fechtali and H. Benomar (Casablanca ; Mohammedia ; Maroc)
  • DNA methylation at selected CPG sites in peripheral blood leukocytes is predictive of gastric cancer. A. Dauksa, A. Gulbinas, Z. Endzinas, J. Oldenburg and O. El-Maarri (Kaunas, Lithuania; Bonn, Germany)
  • Desmoplastic small round cell tumor of the peritoneal cavity with secondary metastatic pleural implants. N. Tsoukalas, M. Kiakou, E. Vogiatzi, K. Liosi, A. Katsimardos, K. Mpallasis, D. Sabaziotis, G. Dimitrakopoulos, C. Christofyllakis (Athens, Greece)
  • Discordance in expressing BRAF gene mutations between primary melanoma and metastases. N. Tsoukalas, M. Kiakou, K. Liosi, M. Giaouraki, E. Vogiatzi, A. Katsimardos, A. Karampeazis, K. Mpallasis, C. Christofyllakis (Athens, Greece)
  • Simultaneously appearance of a testicular cancer and a thyroid carcinoma in young male. N. Tsoukalas, M. Kiakou, M.Giaouraki, E. Vogiatzi, K. Liosi, A. Katsimardos, A. Karampeazis, K. Mpallasis, C. Christofyllakis (Athens, Greece)
  • Clinicopathological characteristics of testicular cancer: a 10-year experience of a medical oncology department. N. Tsoukalas, S. Siakavellas, X. Bitsi, M. Kiakou, K. Liosi, E. Vogiatzi, A. Katsimardos, N. Xolis, A. Karampeazis, K. Mpallasis, C. Christofyllakis (Athens, Greece)
  • Uncommon spread of breast cancer with metastatic infiltration only to rotter’s lymph nodes. N. Tsoukalas, N. Salemis, G. Nakos, M. Kiakou, K. Liosi, E. Vogiatzi, A. Katsimardos, K. Mpallasis, C. Christofyllakis (Athens, Greece)
  • Uncommon late recurrence of a testicular seminoma with a metastatic lesion to colon. N. Tsoukalas, N. Salemis, G. Nakos, G. Boubousis, M. Kiakou, K. Liosi, E. Vogiatzi, A. Katsimardos, K. Mpallasis, C. Christofyllakis (Athens, Greece)

44. NUTRITION AND CANCER. NUTRITIONAL ASPECTS OF CANCER PREVENTION

ROOM B, 16.15-18.45 – Wednesday, October 8

Chair Person : G. Vollmer, S.A. Lamprecht, N. Abu Freha

  • Developmental programming in experimental breast cancer. G. Vollmer, M. Muders, O. Zierau, F.J. Möller (Dresden, Germany) (30’)
  • Dysmetabolism and cancer. Association and clinical outcomes. S. Riondino, P. Ferroni, R. Palmirotta, M. Roselli, F. Guadagni (Rome, Italy) (20’)
  • Cancer, nutrition and more: the nature-deficit-effect and the origin of cancer. J. Spitz, A. Spitz (Schlangebad, Germany) (30’)
  • Bacterial mutagenicity studies on bottled mineral water samples. K. Szendi, Z. Kontár, G. Gerencsér, K. Berényi, C. Varga (Pécs, Hungary) (10’)
  • Cytostatic drugs and dietary supplements – Clinically relevant interactions? A. Farkouh, A. Georgopoulos, M. Czejka (Vienna, Austria) (15’)
  • Correlations of Vitamin D blood levels with beta catenin and p53 expression in precancerous and cancerous human colon. A. Juniku-Shkololli, S. Manxhuka-Kerliu, H. Ahmetaj, V. Khare, S. Zekaj (Prishtina, Republic of Kosovo; Vienna, Austria) (10’)

44P. NUTRITION AND CANCER. NUTRITIONAL ASPECTS OF CANCER PREVENTION (POSTER)

  • A health promotion program in a hungarian roma community: nutritional aspects. Z.S. Orsós, E. Nagy-Borsi, I. Kiss (Pécs, Hungary)

45. NEW ANTICANCER AGENTS

ROOM C, 08.00-15.00 – Wednesday, October 8

Chair Persons: S. Sarkar, P. Collery

  • Epigenetic changes in cancer cells and development of a combination therapy. S. Sarkar (Boston, MA, USA) (30’)
  • Nanotherapy with empty liposomes for carcinoma. Y. Matsumoto (Kumamoto, Japan) (30’)
  • A novel, selective small molecule inhibitor of protein kinase CK2 induces significant cell death in vitro and in tumor xenograft models. B. Guerra, T.D.L. Rasmussen, A. Schnitzler, H.H. Jensen, B.S. Boldyreff, Y. Miyata, N. Marcussen, K. Niefind, O.G. Issinger (Odense, Denmark; Cologne, Germany; Kyoto, Japan) (40’)
  • Combination of three metals for the treatment of cancer: Gallium, Rhenium and Platinum. 2. The Conclusion. P. Collery, J. D’Angelo, A. Mohsen, A. Kermagoret, A. Tomas, T. Collery, M. Wei, A. Badawi, D. Desmaele (Algajola; Chatenay-Malabry; Paris; MaisonsAlfort, France; Cairo, Egypt) (20’)
  • Disulfiram, an anti-alcoholism drug, giving new hope to cancer patients. P. Liu, Z. Wang, S. Brown, V. Kannappan, P.E. Tawari, A.L. Armesilla, W. Wang (Wolverhampton, UK) (30’)
  • The effect of GcMAF complexed with oleic acid on multiple myeloma cultures. R.J. Smith, E. Ward, J.J.V. Branca, M. Ruggiero, G. Morucci, S. Pacini (Cambridge, UK; Firenze, Italy; Bayreuth, Germany) (30’)
  • 1,4-Dihydropyridines and related compounds as potential anticancer drugs. G. Duburs, A. Krauze, E. Bisenieks, B. Vigante, A. Plotniece, I. Bruvere, S. Grinberga, I. Shestakova, I. Domracheva, E. Jaschenko, N. Zarkovic, J. Molnar (Riga, Latvia; Zagreb, Croatia; Szeged, Hungary) (30’)

Chair Persons: J. Anastassopoulou, S. Kottaridis

  • Tanshinone IIA could inhibit gastric carcinoma AGS cells through increasing p-p38, p-JNK and p53 but decreasing p-ERK, Cdc2 and cyclin B1 expression. C.C. Su (Changhua, Taiwan) (10’)
  • Protein and polymeric nanoparticles for cancer therapy: Synthesis, characterization, drug release and interaction with a breast cancer cell line (MCF-7). O. Akbal, E. Erdal, T. Vural, D. Kavaz, E.B. Denkbas (Ankara, Turkey; Nicosia, Cyprus) (15’)
  • Photodynamic therapy in canine and feline cancer treatment using the photosensitizer Bremachlorin. A. Roos, J.V.F.Tan, P.B.A.A. van Driel, T.J.A. Snoeks, M. van Vliet, C.G.W.M. Lowik (Gouda, Netherlands) (10’)
  • Oxaliplatin together with PPAR ligands induce anti-proliferative effects in human colon and prostate cancer cells. N. Strakova, J. Hofmanova, O. Zapletal, K. Soucek, R.Ferd, J. Bouchal, Z. Kolar, A. Kozubik (Brno; Olomouc, Czech Republic) (10’)
  • N(4)-boronated derivatives of 2’-deoxycytidine as potential BNCT agent. J. Niziol, Z. Zielinski, P. Maj, W. Rode, T. Ruman (Rzeszów; Warsaw, Poland) (15’)
  • Will we ever find a better anthracycline? M. Lukawska (Warsaw, Poland) (10’)

45P. NEW ANTICANCER AGENTS (POSTER)

  • The mechanism of synergism between 5-fluorouracil and 2-oxohexyl isothiocyanate in the colon cancer cell line HT-29. M. Milczarek, K. Wiktorska, L. Sliwka, K. Lubelska, K. Dabrowska, D. Matosiuk, Z. Chilmonczyk (Lublin; Warsaw, Poland)

46P. EXPERIMENTAL CHEMOTHERAPY(POSTERS)

  • Validation of antitumor effect by intravenous administration of CRM197 in triple negative breast cancer. S. Fukagawa, S.O. Nam, F. Yotsumoto, K. Miyata, M. Kuroki, S. Miyamoto (Fukuoka, Japan)
  • Thioxanthone compounds to reduce tumor growth, cancer cachexia, and cancer treatment related bone marrow toxicity. G. Spengler, I. Mucsi, F. Uher, P. Hegyes, O. Csuka, J. Molnar, Z. Kiss (Szeged; Budapest, Hungary; Austin, Minnesota, USA)
  • In vivo visualization of electro-assisted delivery of nanoparticles using optical imaging. S. Atanasova, D. Lazarova, B. Nikolova, Z. Zhelev, I. Tsoneva, I. Aoki, R. Bakalova (Sofia; Stara Zagora, Bulgaria; Chiba, Japan)
  • Photodynamic therapy- A review and its role in the management in malignant disorders. B. Ziolkowska, M. Wozniak, K. Szachniewicz-Dus, P. Ziolkowski (Wroclaw, Poland)
  • Optimization of a syngeneic mouse tumor model with magnetic nanoparticles for pre-clinical screening of new anticancer agents. K. Spyridopoulou, A. Tiptiri-Kourpeti, K. Simeonidis, I.M. Koukourakis, O. Kalogirou, K. Chlichlia (Alexandroupolis; Thessaloniki, Greece)
  • Autophagy and apoptosis analysis on T24 and 5637 cells induced by carboplatin and piroxicam. J. Silva, R. Pinto-Leite, A.I. Faustino-Rocha, A. Colaço, R. Arantes-Rodrigues, P.A. Oliveira (Vila Real, Portugal)
  • Carboplatin and piroxicam effects on human urinary bladder cancer cell lines. J. Silva, R. Pinto-Leite, A.I. Faustino-Rocha, A. Colaço, R. Arantes-Rodrigues, P.A. Oliveira (Vila Real, Portugal)
  • Role of chlorogenic acid in suppressing 5-fluorouracil induced renal oxidative stress, apoptosis and inflammation in Wistar rats. S. Rashid, S. Sultana (New Delhi, India)

47. CANCER SURGERY

ROOM C, 15.15-19.30 – Wednesday, October 8

Chair Persons: T. Yoshizumi, N. Tsoukalas

  • Living donor liver transplantation for hepatocellular carcinoma within Milan criteria. T. Yoshizumi, K. Shirabe, T. Ikegami, N.Harimoto, S. Itoh, K. Takeishi, Y. Yamashita, H.Kawanaka, T. Ikeda, Y.Maehara (Fukuoka, Japan) (30’)
  • Clinical results of repeat hepatectomy for recurrent hepatocellular carcinoma: A single-center experience. Y. Yamashita, K. Shirabe, K. Takeishi, S. Itoh, N. Harimoto, T. Ikegami, T. Yoshizumi, H. Kawanaka, T. Ikeda, Y. Maechara (Fukuoka, Japan) (20’)
  • Prognostic impact of EGFR driver mutations on postoperative recurrence in non-small cell lung cancer. T. Okamoto, H. Kitahara , S. Shimamatsu, M. Katsura, K. Takada, T. Fujishita, Y. Suzuki, Y. Morodomi, T. Tagawa, Y. Maehara (Fukuoka, Japan) (10’)
  • The role of transanal endoscopic microsurgery in rectal tumours: Organ sparing multi-modality treatment. S. Papagrigoriadis (London, UK) (20’)
  • Neoadjuvant chemoradiotherapy followed by surgery and salvage surgery for the patients with clinical T3/nearly T4 esophageal cancer. H. Saeki, S. Tsutsumi, T. Yukaya, H. Tajiri, Y. Tsuda, Y. Kasagi, Y. Zaits, K. Ando, Y. Nakashim, Y. Imamura, K. Ohgaki, Y. Maehara(Fukuoka, Japan) (10’)
  • Conservative treatment for patients with osteoid osteoma: A case series. H. Aiba, K. Hayashi, H. Inatani, Y. Satoshi, N. Watanabe, K. Sakurai, H. Tsuchiya, T. Otsuka (Nagoya; Seto, Aichi; Kanazawa, Kanazawa, Japan) (10’)

Chair Persons: T. Okamoto, H. Saeki

  • Pancreatic neuroendocrine tumors: an overview and algorithm of management. N. Tsoukalas (London, UK) (30’)
  • Magnetic-guided cancer surgery. M. Ahmed, B. Anninga, M. Douek (London, UK) (20’)
  • Prognostic factors for long-term survival after distal pancreatectomy for pancreatic adenocarcinoma. a single-centre experience. T. Dumitrascu, S. Dima, C. Stroescu, V. Brasoveanu, L. David, O. Stanciulea, A. Scarlat, V. Herlea, M. Ionescu, I. Popescu (Bucharest, Romania) (15’)
  • Prognostic factors after surgery for pancreatic neuroendocrine tumors: A single center experience. S.O. Dima, V. Herlea, T. Dumitrascu, C. Stroescu, O. Stanciulea, D. Tomescu, N. Bacalbasa, L. David, F. Botea, R. Purtan, A. Croitoru, C. Gheorghe, I. Popescu (Bucharest, Romania) (15’)
  • Robotic approach in pancreatic tumors. O. Stanciulea, S. Dima, T. Dumitrascu, I. Popescu (Bucarest, Romania) (15’)
  • Ureteral reimplantation after resection of alocally invasive in the ureteral ostium cervical tumor – a case report. N. Bacalbasa, S.O. Dima, I. Balescu (Bucharest, Romania) (10’)
  • The role of extensive upper abdominal surgery in advanced ovarian cancer – a case report. N. Bacalbasa, S.O. Dima, I. Balescu (Bucharest, Romania) (10’)

47P. CANCER SURGERY (POSTERS)

  • Intragastric SILS for GIST, a new challenge in oncologic surgery: first experiences. K. De Vogelaere, N. Van De Winkel, C. Simoens, G. Delvaux (Brussels, Belgium)
  • Skin cancer incidence: a six year retrospective analysis. I. Lintzeris, X. Agrogianni, A. Lintzeri, G. Chatzoulis, G. Vourliotakis, V. Ponirakos, A. Varatsos (Tripoli ; Athens, Greece)
  • Prevalence of metallo-beta-laktamase producing pseudomonas aeruginosa in surgical oncology patients. I. Lintzeris, G. Kaklamanis, M. Dimitriou, X. Agrogianni, I. Spiliotis, I. Nomikos, V. Papaemanouil(Athens, Greece)
  • Radiofrequency ablation in primary colo-rectal cancer and liver metastasis. C. Cirimbei, V. Prunoiu, M. Marincas, S. Cirimbei, I. Stefan, D. Straja, E. Bratucu(Bucharest, Romania)

48. BRAIN CANCER TREATMENT: EPIGENETIC NETWORKS
Special Symposium Organized by E. Benericetti and R. Nano

ROOM D, 8.00-15.00 – Wednesday, October 8

Chair Persons: E. Benericetti, R. Nano, D. Schiffer

  • Glioblastoma: microenvironment and perivascular and perinecrotic niches. D. Schiffer, L. Annovazzi, C. Casalone, P. Cassoni, M. Mellai (Vercelli, Italy) (40’)
  • Cytotoxic evaluation of iron nanoparticles covered by rhamnose sugar in glioblastoma and endothelial cell lines. A. Paolini, A. Lascialfari, R. Nano (Pavia; Milan, Italy) (40’)
  • Glioblastoma stem cells radioresistance: evaluation of the potential benefits from carbon ion irradiation. A. Facoetti, R. Nano (Pavia, Italy) (40’)
  • DNA damage and repair cascade after chemotherapeutic drugs in glioblastoma cell lines. L. Annovazzi, M. Mellai, V. Caldera, D. Schiffer (Vercelli, Italy) (30’)
  • Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas. M. Mellai, A. Piazzi, L. Annovazzi, D. Schiffer (Vercelli, Italy) (30’)
  • Magnetic nanoparticles : recent advances in biomedical applications. P. Arosio, A. Lascialfari, M. Corti, T. Orlando, L. Bordonali, F. Orsini (Milano ; Modena ; Pavia, Italy) (15’)
  • Epigenetic regulation of tumor growth: micro RNA as biomarkers and possible new drugs. E. Capelli, V. Curti, L. Fassina (Pavia, Italy) (30’)
  • Survival and danger signals expression in glioblastoma cell lines: tumour immunogenicity after radiation and chemotherapy. F. Pasi, A. Paolini, R. Di Liberto, R. Nano (Pavia, Italy) (40’)
  • Uptake evaluation of 18f-fluorocholine vs 18f-fluorodeoxyglucose in T98G glioma cells. D. Cappelletti, F.E. Buroni , L. Lodola, M.G. Persico, R. Nano (Pavia, Italy) (30’)

48P. BRAIN CANCER TREATMENT. EPIGENETIC NETWORKS (POSTER)

  • Focussed transcranial ultrasounds: application to the delivery of glycosylated oleic acid/vitamin d-binding protein to brain tumours and metastases. J.J.V. Branca, S. Pacini, M. Ruggiero (Firenze, Italy; Channel Islands, UK)

49. CLINICAL CHEMOTHERAPY

ROOM D, 15.15-19.30 – Wednesday, October 8

Chair Persons: T. Aoki, J. Slansky, M. I. Panagiotidis

  • Novel therapies in soft tissue sarcoma (STS). I. Judson (London, UK)(30’)
  • Chemotherapy-induced peripheral neuropathy. T. Ohno (Shimabara, Nagasaki, Japan) (30’)
  • Analysis of complete remission in cases with advanced non-small cell lung cancer. T. Aoki, K. Harada, J. Tanaka, M. Sato, Y. Horio, H. Takiguchi, H. Tomomatsu, K. Tomomatsu, T. Takihara, K. Niimi, N. Hayama, T. Oguma, T. Akiba, T. Komatsu, T. Nakagawa, R. Masuda, T. Urano, E. Kunieda, Y. Oizumi, M. Iwazaki, K. Asano (Isehara, Kanagawa, Japan) (30’)
  • Therapeutic effectiveness of hyperthermia in malignant melanoma. M.I. Panagiotidis (Edinburgh, Scotland, UK) (40′)
  • Thyroid disorders as potential predictive clinical marker of better treatment response to sunitnib therapy. D. Kust, M. Prpic, J. Murgic, M. Jazvic, B. Jakšic, D. Krilic, A. Bolanca, Z. Kusic (Zagreb, Croatia) (20’)
  • Therapeuticstrategies in the 1st line treatment of patients with NSCLC harboring EGFR mutations. A. Rapti (Athens,Greece) (20’)
  • NBTXR3 nanosized radioenhancer: effective cell killing in the clinic. J. Marill, S. Vivet, P. Zhang, A. Pottier, P. Said, M. Dimitriu (Paris, France) (15’)
  • Prediction of the fast tumoricide effect of transarterial application of 90-yttrium glass-microspheres, a potential role of dual-energy ct (review). J. Ferda, P. Duras, V. Treška, T. Skalický, J. Fínek, O. Topolcan (Pilsen, Czech Republic) (15’)
  • AntiHer2 Targeted therapy in advanced gastric cancer. W. Mahfoud, H. Amrani Hassani Joutei, I. Saadaoui, N. Elgnaoui, H. Lebrazi, H. Benomar (Casablanca, Morocco) (10’)

49P. CLINICAL CHEMOTHERAPY (POSTERS)

  • Strategy for synchronous and multiple liver metastasis. S. Osada, H. Imai, Y. Sasaki, K. Yoshida (Gifu, Japan)
  • Radiation recall dermatitis: new case report with targeted therapy. A. Frikha, L. Le Pellec, G. Nivard, J. Orabona, G. Estevez, A. Ginot (Bastia, France)
  • Nagalase and the rational use of macrophage activating factor (GcMAF) in the clinical treatment of chronic fatigue syndrome/myalgic encephalomyelitis(CFS/ME) and CFS/ME-related disorders. K. De Meirleir, T. Mijatovic, C. Roelant (Neder-Over-Heembeek; Zellik, Belgium)
  • A neuroendocrine approach in the treatment of brain glioblastoma. E. Porta, G. Messina, G. Porro, P. Lissoni (Milan, Italy)
  • Combination of chemoradiotherapy for hypopharyngeal cancer with usage of ftorafur and cisplatin. D. Sakaeva, A. Sultanbaev (Bhashkortostan, Russia)
  • A γH2AX study in mouse liver nctc cells following irradiation (with and without amifostine). S. Pouliliou, D. Kalamida, M.I. Koukourakis (Alexandroupolis, Greece)
  • Pepride receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumors: The University General Hospital of Athens ’’ATTIKON’’ paradigm. T. Liotsou, A.P. Stefanoyiannis, S.N. Chatziioannou (Athens, Greece)
  • Influence of hormone profile on vascular endothelial growth factor (VEGF a) expression in human pituitary adenomas. E. Melnic, A.M. Cimpean, A.R. Balica, P.N. Gaje, M. Raica (Chisinau, Moldova; Timisoara, Romania)

50. PKC SIGNALING IN CANCER
Special Symposium Organized by A.P. Fields

ROOM E, 08.00-12.00 – Wednesday, October 8

Chair Person: A.P. Fields

  • Tumor suppressor activity of protein kinase C a in epithelial cancers. J.D. Black (Omaha, NE, USA) (30’)
  • PKCs in vivo function analysed by gene targeting in mice. M. Leitges (Oslo, Norway) (30’)
  • Protein kinase C delta regulates cell proliferation and cell death. M.E. Reyland, J.M. Symonds, A.M. Ohm (Aurora, CO, USA) (30’)
  • Targeting atypical protein kinase Cs for pancreatic cancer therapy. N.R. Murray (Jacksonville, FL, USA) (30’)
  • Protein kinase Cδ signaling mechanisms in lung cancer initiation and maintenance. V. Justilien, M.P. Walsh, S.A. Ali, E.A. Thompson, N.R. Murray, A.P. Fields (Jacksonville, FL, USA) (30’)

51. HEPATOCELLULAR CARCINOMA
Special Symposium Organized by K. Kubota

ROOM E, 13.00-15.00 – Wednesday, October 8

Chair Person: K. Kubota

  • Anatomical liver resection for hepatocellular carcinoma. K. Kubota, T. Matsumoto (Tochigi, Japan) (20’)
  • High dorsal rejection of the liver for patients with HCC. T. Takayama (Tokyo, Japan) (20’)
  • Living donor liver transplantation for patients with HCC in Japan. S. Kawasaki (Tokyo, Japan) (20’)
  • Therapeutic strategy of hepatocellular carcinoma by laparoscopic hepatetomy. H. Kaneko, Y. Otsuka (Toho, Japan)(20’)
  • RF ablation for HCC in Japan. R.Tateishi (Tokyo, Japan) (20’)

52. INVASION AND CARCINOMAS OF THE GI TRACT
Special Symposium Organized by O.D. Laerum

ROOM E, 15.10-17.10 -  Wednesday, October 8

Chair Person: O.D. Laerum

  • Introduction. O.D. Laerum (Bergen, Norway)
  • Expression of the urokinase receptor (UPAR) in gastric adenocarcinomas and non-neoplastic gastric mucosa. W. Alpízar-Alpízar, M. Illemann, M.E. Skindersø, L. Rasmussen, I.J. Christensen, A. Skarstein, K. Ovrebo, I.K. Lund, K.A. Krogfelt, L.P. Andersen, M. Ploug, O.D. Laerum (San José, Costa Rica; Copenhagen, Denmark; Bergen, Norway) (20’)
  • Molecular biology of colorectal cancer: life after NGS. M. Ilyas (Nottingham, UK) (20’)
  • Pericellular proteolysis generated by tumour-associated macrophages and fibroblasts is a hallmark of invasive colorectal cancer. M. Illemann (Copenhagen, Denmark) (20’)
  • Importance of plasminogen activator receptor ( uPAR) for the spread of esophageal adenocarcinomas as compared to other carcinomas of the GI tract. O.D. Laerum (Bergen, Norway) (40’)

53. DRUG RESISTANCE IN CANCER AND TARGETING DNA REPAIR PATHWAYS
Special Symposium Organized by S. Mitra and B. Kaina

ROOM E, 17.20-19.30 – Wednesday, October 8

Chair Persons: S. Mitra, B. Kaina

  • Exploring DNA repair as a target in cancer therapy. S. Adhikari, M.L. Hegde, S. Mitra (Houston, TX, USA) (40’)
  • DNA Repair and radiation and drug sensitivity of human blood cell populations. B. Kaina, M. Bauer, D. Heylmann, V. Ponath, M. Eich (Mainz, Germany) (30’)
  • RECQ1 mediates cancer cell resistance to combination therapy of PARP inhibitor and alkylating chemotherpeutic agents. R. Roy (Washington, DC, USA) (40’)

54. BIOBANKS: A RESEARCH INFRASTRUCTURE FOR THE FUTURE OF TRANSLATIONAL AND CLINICAL RESEARCH
Special Symposium of the International Society for Biological and Environmental Repositories (ISBER), Organized by F. Betsou and F. Guadagni

ROOM F, 8.00-14.00 – Wednesday, October 8

Chair Persons: F. Guadagni, E. Briasoulis
Introduction : F. Guadagni

  • Biobank standardization and the ISBER contributions. F. Betsou (Luxembourg) (25’)
  • Establishing a quality-oriented Academic Cancer Biobank: an interdisciplinary initiative of the University of Ioannina, Greece. E. Briasoulis, E. Hatzimichael, A. Dasoula, I. Sainis, Y.C. Stamatiou, M. Fatouros (Ioannina; Rio, Patras, Greece) (25’)
  • An Italian experience in biobanking research: the involvement of BioBIM in inter-regional research projects. F. Guadagni (Rome, Italy) (25’)
  • Lifecycle of specimens and data intelligence in a biobank: some models and case studies with BioBIM. U. Nanni (Rome, Italy) (25’)

Chair Persons: F. Betsou, M. Roselli

  • Qatar Biobank, a comprehensive data and sample resource to support future healthcare initiatives. H. Abderrahim (Doha, Qatar) (25’)
  • What can go wrong and how to avoid it – The experience of the IBBL. D. Allen (Luxembourg) (20’)
  • Biobanking Standard Operative Procedures (SOPs) for molecular biology applications. R. Palmirotta (Rome, Italy) (20’)
  • Benefits of an Italian SME participating to a biobanking project co-funded by the European Regional Development Fund (ERDF) (P.O. F.E.S.R. Sicilia 2007-2013). M. L. Ontario (Catania, Italy) (20’)
  • Innovation in the biomedical industry, R&D investments and collaborations between industry and the scientific and technological research. S. Ontario (Catania, Italy) (20’)
  • Biobanks: translational and clinical implications. M. Roselli (Rome, Italy) (20’)

Conclusion : F. Betsou


55. HYPOXIA AND CANCER CELL PROTECTION IN CANCER METASTASIS
Special Symposium Organized by G. Rutterman

ROOM F, 14.15-18.30 – Wednesday, October 8

Chair Persons: G. Rutteman, J.T. de Oliveira

  • Stromal hypoxia and metastasis in breast cancer. H. Rundqvist, C. Stockmann, C. Branco-Price, A. Doedens, R.S. Johnson (Cambridge, UK; Stockholm, Sweden; Essen, Germany) (30’)
  • Elucidating the role of MUC1 in modulating pancreatic cancer cell survival by metabolomic analysis under hypoxic conditions. N.V. Chaika, T. Gebregiworgis, K. Mehla, V. Gunda, R. Powers, P.K. Singh (Omaha, NE, USA) (40’)
  • Inhibition of mTOR stimulates WNT activity and MUC1 expression in mammary carcinoma cell lines. J.A. Mol, E. Timmermans-Sprang, A. Gracanin (Utrecht, The Netherlands) (25’)
  • A truncated active form of VDAC1 is associated with hypoxic cell survival and correlates with tumor progression in lung cancer patients. M.C. Brahimi-Horn, N.M. Mazure (Nice, France) (30’)
  • Hypoxia up-regulates galectin-3 in mammary tumor progression and metastasis. J.T. de Oliveira, C. Ribeiro, G.R. Rutteman, F. Gärtner (Porto, Portugal; Utrecht, The Netherlands) (20’)
  • Sialylation dynamics in the microenvironment of mammary tumours – sialidase uncloaking. J.T. de Oliveira, F. Gärtner (Porto, Portugal) (20’)
  • The HIF-1 target Lysyl oxidase promotes survival and outgrowth of colon cancer cells in the bone marrow, enabling bone metastasis formation. C. Reynaud, L. Ferreras, P. Clézardin (Lyon, France) (25’)

Thursday, October 9


56. CANCER METABOLISM AND AUTOPHAGY

ROOM A, 08.00-12.00 – Thursday, October 9

Chair Persons: R. Clarke, J. Holst

  • Inhibiting autophagy as a strategy to improve antiestrogen responses in breast cancer. K. Cook, A. Wärri, D. Soto-Pantoja, P. Clarke, I. Cruz, A. Zwart, R. Clarke (Washington, DC; Bethesda, MD, USA) (40’)
  • Nutrient regulation coordinates adaptive cancer cell metabolism. J. Holst (Camperdown, NSW, Australia) (40’)
  • MAPK15 mediates BCR-ABL-induced autophagy and cellular transformation. D. Colecchia, M. Chiariello (Siena, Italy) (30’)
  • Modulation of colon cancer cell lipidome and kinetics by dietary fatty acids. J. Hofmanova (Brno, Czech Republic) (30’)
  • LC3A vs. LC3B: two distinct autophagosome markers to consider for experimental and translational studies. M.I. Koukourakis (Alexandroupolis, Greece) (30’)
  • The autophagic responce to photodynamic therapy. B. Ziólkowska, M. Wozniak, K. Dus – Szachniewicz, P. Ziólkowski (Wroclaw, Poland) (10’)
  • Transcription factor EB (TFEB) sustains migratory phenotype of lung cancer cell lines. D. Kalamida (Alexandroupolis, Greece) (20’)

56P. CANCER METABOLISM AND AUTOPHAGY (POSTERS)

  • Progesterone and rapamycin in relation with autophagy on endometrial cancer cell line. S. Muftuoglu, N.D. Zeybek, T. Demirci (Ankara, Turkey)
  • Silencing of LC3 autophagy proteins sensitizes glioblastoma cell lines to radiation. A.G. Mitrakas, D. Kalamida, I.V. Karagounis, S. Pouliliou, A. Giatromanolaki, M.I. Koukourakis (Alexandroupolis, Greece)
  • In vitro characterization of autophagy flux after exposure to ionizing radiation in lung cancer. I.V. Karagounis, D. Kalamida, A.G. Mitrakas, M.V. Liousia, A. Giatromanolaki, M.I. Koukourakis (Alexandroupolis, Greece)

57. INVASION AND METASTASIS

ROOM A, 13.00-16.15 – Thursday, October 9

Chair Persons: J. Carlsson, M. Schauer

  • Imaging of HER2-expression in breast cancer metastases. J. Carlsson (Uppsala, Sweden) (30’)
  • Tissue factor, VCAM-1 and VAP-1 orchestrate the recruitment of macrophages to tumour cells in pulmonary metastasis. A. Gil-Bernabe (Oxford, Oxfordshire, UK) (40’)
  • Direct participation of the metastasis suppressor NME1 in DNA repair pathways. D.M. Kaetzel, G. Cook, S. Jarrett, M.J. Leonard, M. Novak, A. Greenawalt  (Baltimore, MD, USA) (30’)
  • Positioning LMTK3 on the map of oncogenic signaling cascades and elucidating its role in invasion and metastasis in Breast Cancer. G. Giamas, Y. Xu, H. Zhang, C. Vorgias, J. Stebbing (London, UK) (20’)
  • Molecular mechanisms for local invasion and metastases of gastric cancer. Do tyrosine receptors play a role? M. Schauer (Duesseldorf, Germany) (20’)
  • Modified adipose mesenchymal progenitors target ewing’s sarcoma. G. Grisendi, C. Spano, N. D’Souza, V. Rasini, E. Veronesi, S. Piccinno, G. De Santis, E. Horwitz, P. Conte, P. Paolucci, M. Dominici (Modena; Padova, Italy; Philadelphia, PA, USA) (20’)

58. APOPTOSIS

ROOM A, 16.30-19.15 – Thursday, October 9

Chair Persons: B. Kaina, M. I. Panagiotidis

  • Apoptosis, autophagy and DDR triggered by temozolomide. B. Kaina, A. Knizhnik, A. Krumm, M. Eich, W.P. Roos (Mainz, Germany) (30’)
  • Regulation of mitotitc death. T.C. Chambers (Little Rock, AR, USA) (40’)
  • BMX negatively regulates BAK function increasing apoptotic resistance to chemotherapeutic agents in cancer cells. J. Fox, A. Storey (Oxford, UK) (15’)
  • Resistance to UV-induced apoptosis by beta HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase. A. Holloway, M. Simmonds, A. Azad, J. Fox, A. Storey (Oxford, UK) (15’)
  • Hormonally induced apoptosis, related to androgen and GNRH receptor status in prostate cancer. An overview. B. Szende, I. Romics, J. Szabó, G. Bánfi, T. Krenács (Budapest, Hungary) (15’)
  • Hyperthermia-induced cell death in human malignant melanoma. T. Mantso, A. Sfakianos, M.J. Cañavate Sánchez, A. Pappa, G. Goussetis, M. Panagiotidis (Edinburgh, UK; Alexandroupolis, Greece) (15’)

58P. APOPTOSIS (POSTERS)

  • Soluble pro-apoptotic CD95L in normal sera and in sera from breast cancer patients.L. F. Jave-Suárez, V. Olimón-Andalón, S. Ratkovich-González, A. Uribe-López, I. Mariscal-Ramírez, R. Delgadillo-Cristerna, A. Aguilar-Lemarroy (Culiacán, Sinaloa; Culiacán, Sinaloa, Mexico)
  • The importance of PACAP receptors in the rapamycin-treated lung cancer cell line. T. Onal, M. Temel, M. Ozgul, E. Turkoz Uluer, S. Inan, K. Ozbilgin (Manisa, Turkey)
  • Effects on caspases activation of using in combination cis-platin with ε-viniferin in rat glioma cells. N.I. Önder Mert, M. Sen, E. Apaydin, Z. Incesu, F. Özdemir (Eskisehir, Turkey)
  • Combine treatment of cis-platin and ε-viniferin induce c6 (rat glioma) cell apoptosis in time-dependent manner. E. Apaydin, A.Ayrim, N. I. Önder Mert, Z. Incesu, F. Özdemir (Eskisehir, Turkey)
  • Silver-based nanoparticles induce apoptosis in human colon cancer cells mediated through p53. S.R. Satapathy, P. Mohapatra, R. Preet, D. Das, A. Nayak, S. Das, T. Choudhuri, M.D. Wyatt, C.N. Kundu ( Bhubaneswar, Odisha; Santiniketan, West Bengal, India; Columbia, SC, USA)

59. NEW ANTICANCER AGENTS

ROOM B, 08.00-14.30 – Thursday, October 9

Chair Persons : A. Z. Dudek, M. Schneider

  • Kiteplatin – a potential clinical candidate showing significant activity vs. oxaliplatin-resistant colorectal cancer. J.D. Hoeschele, E. Petruzzella, N. Margiotta, G. Natile, V. Gandin and C. Marzano (Ypsilanti, MI, USA; Bari; Padova, Italy) (30’)
  • Opportunities and challenges to develop drugs for treating glioblastoma: A mechanistic prospective. A. Bhushan, A. Jain, J.C.K. Lai (Philadelphia ; Lexington ; Pocatello, USA) (30’)
  • Metal-based anticancer agents basing on TCM active ingredient oxoisoaporphine alkaloids. Z.F. Chen, Q.P. Qin, J.L. Qin, Y.C. Liu, K.B. Huang, Y. Peng, H. Liang (Guilin, P.R. China) (30’)
  • HSV1716 (SEPREHVIR): an oncolytic herpes virus for cancer therapy. L. Braidwood (Glasgow, UK) (30’)
  • Targeted drug delivery to pediatric sarcomas through proprotein convertases binding peptides. P. Jaaks, M. Roveri, V. D’Alessandro, B.W. Schäfer, P. Luciani, M. Bernasconi (Zurich, Switzerland) (20’)
  • A promising novel palladium-saccharinate complex of terpyridine against cancer stem cells. E. Ulukaya (Nilüfer, Bursa, Turkey) (15’)
  • Anticancer activity of novel Vitamin D analogs: structural and functional insights. N. Rochel (Illkirch, France)(20’)
  • Conjugation of anti-cancer drug to phage carrying anti-mica for targeting chemotherapy. A. Phumyen, S. Jantasorn, A. Jumnainsong C. Leelayuwat (Khon Kaen, Thailand) (10’)
  • Alkaloids mixture affects ENT1 and DCK gene expression in pancreatic ductal adenocarcinoma (PDAC): synergistic interaction with gemcitabine in preclinical models of PDAC. N. Funel, L.E. Pollina, G. Genova, U. Boggi, D. Campani (Pisa; Pontedera, Italy) (15’)

Chair Persons: M.  I. Panagiotidis, E. Ulukaya

  • Virotherapy with VSV-INFβ for non-small cell lung cancer. M.R. Patel, B.A. Jacobson, K. Xiong, S. Tang, H. Wang, Y. Ji, A. Kratzke, S.J. Russell R.A. Kratzke (Minneapolis, MN, USA) (10’)
  • Copper(II) complexes of 5-(pyridin-2-yl)-norhydrastinine: crystal structure, cytotoxicity and interaction with DNA. K.B. Huang, Z.F. Chen, Y.C. Liu H. Liang (Guilin, P.R. China) (15’)
  • Synthesis and antitumor mechanism of a new anthracene imidazole hydrazone derivative. Y.C. Liu, H.L. Wang, S.F. Tang, Z.F. Chen, H. Liang (Guilin, P.R. China) (15’)
  • Isothiocyanates as anticancer agents in an in vitro model of human malignant melanoma. A. Sfakianos, T. Mantso, S. Tabaczar, A. Pappa, M. Panagiotidis (Edinburgh, UK; Alexandroupolis, Greece) (10’)
  • Mafosfamide and glufosfamide as new anticancer oxazaphosphorine agents. L. Mazur, M. Opydo-Chanek, M. Stojak, K. Sladowska, K. Blicharski, B. Janota, U. Niemeyer (Krakow, Poland; Bielefeld, Germany) (15’)

59P. NEW ANTICANCER AGENTS(POSTERS)

  • Novel, selective MNK inhibitors as improved tools for oncology target validation. E.A. Bureau, M. Newman, S. Adigun, C. Langham, L. Carnevalli, L. Ruston, Z. Howard, P. Bakrania, A. Kamal, S. Lewis, J. Osborne, J. Brownlees, J. Winter, E. McIver, B. Saxty, K. Hudson A. Merritt (London; Macclesfield, UK)
  • Nelfinavir treatment is augmented by addition of chloroquine to induce selective cell death in mTORC1-driven cells. C.E. Johnson, D.K. Hunt, M. Wiltshire, T.P. Herbert, J.R. Sampson, R.J. Errington, D.M. Davies, A.R. Tee (Cardiff; Leicester, UK)
  • Survivin is down regulated by Viscum album L. in pediatric ewing´s sarcoma cells in vitro. M. Twardziok, C. Delebinski, S. Jäger, A. Eggert, G. Seifert (Berlin; Darmstadt; Niefern-Öschelbronn, Germany)
  • A triterpene-containing mistletoe extract (Viscum album L.) induce apoptosis induction via extrinsic and intrinsic pathway in HL-60 cells. S. Kleinsimon, C.I. Delebinski , M. Twardziok, F. Hoff, S. Jäger, J. Rolff, A. Eggert, G. Seifert (Berlin; Darmstadt; Niefern-Öschelbronn, Germany)
  • Elucidating the effect of photodynamic treatment in combination with 3, 3’ –diindolylmethane on the growth of human epithelial cancer cells. E. Leman, F. Fares (Haifa, Israel; Kiev, Ukraine)
  • Dual PI3K/MTOR inhibitor NVP-BEZ235 has potent anticancer effects on NSCLC harboring wild-type EGFR. Y.L. Chen, S.S. Chen, T.M. Hong (Tainan, Taiwan, ROC)
  • The anti-cancer effect of inula viscosa. Extract on colorectal cancer cell growth using in vitro and in vivo systems. R. Bar-Shalom, F. Fares (Haifa, Israel; Kiev, Ukraine)
  • Novel ferrocenyl chalcones as potential anticancer drugs. G. Mojzisová, J. Mojzis, L. Mirossay, J. Vaskova, P. Perjesi, A. Bomba (Kosice, Slovak Republic; Pecs, Hungary)
  • Evaluation of the cytotoxicity and cellular uptake of ruthenium (II) phthalocyanine complexes in a melanoma cell line. J.A. Uzuelli, L.C.B. Ramos, V.C.O. Souza, F.B. Junior, R.S. da Silva (Ribeirão Preto, SP, Brazil)
  • Mechanisms of action of some new complexes of ruthenium with quinolones as potential antitumoral agents. M.I. Gruia, V. Negoita, M. Vasilescu, M. Panait, I. Gruia, V. Uivarosi (Bucharest, Romania)
  • Anti-cancer effect of a novel palladium (ii) complex by inducing apoptosis on ehrlich ascites carcinoma in Balb/C mice. E.I. Ikitimur-Armutak, K. Sonmez, K. Akgun-Dar, G. Sennazli, A. Kapucu, F. Yigit E. Ulukaya (Istanbul ; Bursa, Turkey)
  • The effects of rapamycine on lung cancer cell line through FOXO and PTEN. S. Inan, M. Ozgul, E. Turkoz Uluer, T. Onal K. Ozbilgin (Manisa, Turkey)
  • MT1/MT2 receptors independent of melatonin against human lung adenocarcinoma cells. P. Plaimee, N. Weerapreeyakul, N.P. Johns, S. Barusrux (Khon Kaen, Thailand)
  • Anti-cancer activity of melatonin derivative on human leukemic cell line. P. Plaimee, N. Weerapreeyakul, P. Puthongking, N.P. Johns, S. Barusrux (Khon Kaen, Thailand)
  • Effects of hesperidin on non-small cell lung cancer cells. E.S. Bireller, Z.B. Cincin, M. Unlu, B. Kiran, Y. Baran, B. Cakmakoglu (Istanbul; Izmir; Kastamonu, Turkey)
  • The anti-cancer activitiy of Verbascum inulifolium Hub.-Mor. against human breast cancer MDA-MB-231 and MCF7 cell lines. Y. Ozay, A. Yildiz, O. Yumrutas, C. Guven, I. Albeniz, I. Bozgeyik, L. Turker Sener, H. Bagis, M. Aydogan Ahbab (Adiyaman; Ankara; Istanbul, Turkey)
  • Effect of selected flavonoids on colon carcinoma cells in vitro. M. Wózniak, A. Rogula, I. Flecka, P. Ziólkowski (Wroclaw, Poland)
  • Some aspects of the mechanism of cell death induction by the lipids of N-acyl dopamines family in PC12 cancer cell line. M.G. Akimov, A.M. Ashba, N.M. Gretskaya, V.V. Bezuglov (Moscow, Russia)
  • Complex of cu(II) with a curcumin derivative as antitumor agent. I. Roupa, C. Methenitis, P. Alexiou, M. Sagnou, M. Pelecanou, M. Paravatou-Petsotas (Athens, Greece)
  • Complexes of Pt(II), Pd(II) and Cu(II) with benzothiazole derivative as potent anticancer agents. B. Mavroidi, M. Pelecanou, M. Paravatou-Petsotas, M. Sagnou, C. Methenitis (Athens, Greece)
  • The synergic and additive interaction between selol and sulforaphane isothiocyanate in breast and colon cancer cell lines. L. Sliwka, M. Milczarek, S. Mielczarek, K. Lubelska, P. Suchocki, K. Wiktorska (Warsaw; Lublin, Poland)
  • Antidepressant drugs modify of cytotoxic effect of temozolomide on human glioblastoma cells: In vitro studies. A.M. Bielecka , E. Obuchowicz (Katowice, Poland)

60. ADVANCES IN PROSTATE CANCER

ROOM B, 14.45-19.00 – Thursday, October 9

Chair Persons : K. De Meirleir, D. Sliva

  • Late events in chemotherapy-treated prostate cancer patients: Circulating LDH, CgA and CrP values. P. Bouffette, S. Buhic, K. Kovacic, M. Tarle (Dubrovnik; Zagreb, Croatia) (20’)
  • Relationship between signalling cross-talksbetween the epidermal growth factor receptor (EGFR), c-Met and c-Src and prostate tumour cell response to clinical tyrosine kinase inhibitors. S. Rao, A.L. Larroque-Lombard, B. Allal, J. Jean-Claude Bertrand (Montreal, Canada) (30‘)
  • Will extreme hypofractionation in prostate radiotherapy improve clinical outcome? A. Dasu, I. Toma-Dasu (Linköping, Sweden) (15’)
  • Mistakes in prostatic carcinoma assessment on multiparametric 3t mri: non-pirads and pirads evaluation versus whole-mount section histology. J. Ferda, J. Kastner, E. Ferdová, J. Baxa, R. Fuchsová, M. Hora, O. Hes, O. Topolcan (Pilsen, Czech Republic) (15’)
  • How the war on cancer was lost: strategies for winning. A.A. Sinha (Minneapolis, MN, USA) (40’)

Chair Persons: A. A. Sinha, M. Tarle

  • Anticancer effect of prosta caid: A research overview from laboratory to clinical response. D. Sliva, I. Eliaz (Indianapolis, IN; Santa Rosa, CA, USA) (30’)
  • Stereotactic body radiotherapy in prostate cancer: where are we going? B. De Bari, L. Lestrade, F. Alongi (Lausanne; Geneva, Switzerland; Negrar; Verona, Italy) (20’)
  • Vitamin D deficiency in patients with prostate cancer. K. Wieczorek, R.S. Braczkowski, B. Braczkowska (Katowice, Poland) (15’)
  • Prostate-specific antigen variations in Moroccan patients with histologically proven benign prostatic hyperplasia. I. Sadaoui, W. Mahfoud, H. Amrani Hassani Joutei, N. Elgnaoui, A. Seddiki, H. Benomar, S. Nadifi (Casablance, Morocco) (15’)
  • NF- κB nuclear localization and its prognostic in Moroccan patients with hormono-refractory prostate cancer. I. Sadaoui, V. Brrès, B. Péant, H. Amrani Hassani Joutei, W. Mahfoud, H. Benomar, A.-M. Mes Masson, F. Saad, S. Nadifi (Casablanca, Marocco, Montreal, QC, Canada) (15’)

60P. ADVANCES IN PROSTATE CANCER (POSTERS)

  • Cyclooxygenase 2 genotypes and its association with prostate cancer risk among Japanese populations. S. Sugie, H. Tsukino, S. Mukai, T. Kamoto (Miyazaki, Japan)
  • Improved method for alpha-n-acetyl galactosaminidase (nagalase) testing. B. Thewissen, T. Mijatovic, K. De Meirleir, E. Bosmans (Zonhoven; Zellik; Neder-Over-Heembeek, Belgium)
  • Serum levels of markers in early detection of prostate cancer. R. Fuchsova, O. Topolcan, J. Windrichova, M. Hora, R. Kucera, O. Dolejsova, L. Pecen, P. Kasik (Pilsen, Czech Republic)

61. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM C, 08.00-15.15 – Thursday, October 9

Chair Persons: F. Lumachi, R. Nagler,  D. Schiffer

  • Inter-laboratory pre-validation of the FOCUS4 personalised therapy trial. S.D. Richman, R. Adams, P. Quirke, R. Butler, G. Hemmings, H. Stuart, M. James, S. Wozniak, Bathia R, Pugh C, Maughan T, Jasani B, on behalf of FOCUS4 Trial management Group (Leeds; Cardiff; London; Oxford, UK) (30’)
  • Pancreatic cancer – novel diagnostics and targeted therapy. R. Andersson (Lund, Sweden) (30’)
  • Malignancy-related hypercalcemia: Pathophysiology and diagnosis. F. Lumachi, S.M.M. Basso (Padova; Pordenone, Italy) (30’)
  • 1000 patient study of detection of colorectal cancer and colorectal polyps by serum ELISA of altered epigenetic signatures in circulating cell-free nucleosomes. M. Herzog, L. Rasmussen, I.J. Christensen, H.J. Nielsen, M. Chapelier, G. Cuvelier, K. Scoubeau, E. Josseau, D. Pamart, M. Eccleston, J. Micallef (Namur, Belgium; Hvidovre, Denmark) (15’)

Chair Persons: R. Andersson, K. Guzinska-Ustymovicz

  • Salivary tumor markers for oral and oropharyngeal cancer. R. Nagler (Haifa, Israel) (30’)
  • The Digital Cancer Patient. C. Sansom, V. Diaz-Zuccarini (London, UK) (20’)
  • Nuclear receptors in pancreatic tumorcells. C. Damaskos, T. Karatzas, I.D. Kostakis, L. Nikolidakis, A. Kostakis, G. Kouraklis (Athens, Greece) (10’)
  • Proteomics approaches to identifying proteins involved in adenoma-to-colorectal carcinoma progression. K. Dus-Szachniewicz, P. Ostasiewicz, P. Ziólkowski, M. Wozniak, B. Ziólkowska, M. Mann, J.R. Wisniewski (Wroclaw, Poland) (10’)

Chair Persons: P. Dziegiel, C. Sansom

  • Invasive micropapillary carcinoma as a new histological type of adenocarcinomas in the colorectal cancer. K. Guzinska-Ustymowicz, K. Niewiarowska, A. Pryczynicz (Bialystok, Poland) (10’)
  • Predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFT therapy? N. Marchoudi, H. Amrani Hassani Joutei, F. Jouali, J. Fekkak, H. Rhaissi (Mohammedia; Casablanca, Morocco) (15’)
  • Assessment of shoulder and neck dysfunction and functional status post radiotherapy/chemotherapy in head and neck cancer patients: a pilot study. P.K. Ghotra, S. Saini, A. Malhotra(Ludhiana, India) (15’)
  • Cancer communication: Researchers, doctors, patients and the worried well. C. Sansom (London, UK) (15’)
  • IGF1 serum levels in malignant melanoma and healthy subjects. R. Kucera, I. Treskova, J. Vrzalova, S. Svobodova, O. Topolcan, R. Fuchsova, V. Treska, T. Kydlicek (Prague, Czech Republic) (15’)
  • Association between Fuhrman grade and IGFs family genes expression in clear cell renal cell carcinoma. R.S. Braczkowski, M. Bialozyt, B. Braczkowska, L. Dul(Bytom; Katowice, Poland) (15’)

61P. DIAGNOSIS AND PROGNOSIS OF CANCER (POSTERS)

  • EpCAM overexpression in neuroendocrine gastrointestinal tumors. C. Ensinger, S. Reinold, D. Galler, R. Prommegger (Innsbruck, Austria)
  • Clinical efficiency of 18F-FDG-PET in patients with hepatocellular carcinoma: Explorative analysis of retrospective data of 80 patients. P. Anner, A. Babajew, W. Wadsak, M. Hacker, G. Karanikas (Vienna, Austria)
  • A rare case of an extraneural ependymoma in the pelvic cavity. A case report. E. Smolle, M. Smolle, F. Ronaghi, H. Rogatsch, F. Moinfar, J. Haybaeck (Graz; Veit/Glan; Klagenfurt am Wörthersee, Austria)
  • 18FDG PET/MDCT split-bolus technique by using imaging fusion in oncologic patients. M. Scialpi, L. Pierotti, G. Rosi, S. Gravante, V. Rondoni, M. Iannone, L. Coppola, G. Falcone, A. Rebonato, B. Palumbo (Perugia, Italy)
  • Role of 3.0 T multiparametric MRI (mp-MRI) by pelvic phased-array coil: a rationale approach for prostate cancer detection and management. G. Rosi, A. Nuti, I. Piscioli, S. Gravante, V. Rondoni, B. Palumbo, A. Rebonato , M. Scialpi (Perugia; Bologna, Italy)
  • The growth differentiation factor-15 (GDF-15) can be useful in the detection of distant metastases in sera of colorectal cancer patients. K. Guzinska-Ustymowicz, K. Niewiarowska, A. Pryczynicz, V. Dymicka-Piekarska, W. Famulski, M. Gryko, D. Jagodzinska, A. Kemona (Bialystok, Poland)
  • The immunohistochemical studies on melanoma-associated antigen D2 (MAGED2) expression profile in colorectal cancer. K. Dus-Szachniewicz, P. Ostasiewicz, M. Wozniak M,P. Kolodziej, B. Ziólkowska, P. Ziólkowski (Wroclaw; Walbrzych, Poland)
  • Common DNA excision repair gene variants may influence the outcome in non-small cell lung cancer treated with definitive radiotherapy. D. Butkiewicz, M. Krzesniak, M. Giglok, A. Drosik, B. Maslyk, I. Matuszczyk, M. Rusin, R. Suwinski (Gliwice, Poland)
  • The use of deleted 133p53 as a prediction marker for chemo-responsiveness in cholangiocarcinoma. N. Nutthasirikul, T. Limpaiboon, C. Leelayuwat, C. Hahnvajanawong, T. Techasen,P. Jearanaikoon (KhonKaen, Thailand)

62. RADIOTHERAPY

ROOM C, 15.30-17.30 – Thursday, October 9

Chair Persons: L. Trigo, N. Nguyen

  • Accelerated partial breast irradiation (APBI) with multicatheter interstitial brachytherapy over 11 years of practice. A. Aguiar, L. Trigo, N. Stas (Porto, Portugal) (20’)
  • High-dose irradiation do not modify the immunosuppressive effects elicited by cancer-associated fibroblasts. T. Hellevik, L. Gorch, T.B. Stuge, I. Martinez-Zubiaurre (Trømso, Norway) (20’)
  • The impact of radiation oncology evolution on the incidence of radiation induced cranial nerves palsy in patients with head and neck cancer. W.F. Mourad (New York, NY, USA) (30’)
  • Treatment of refractory cancer pain: what can we expect from image guided interventional techniques? B. Kastler, H.Alnassan, X. Wang, A. Kastler (Besançon, France) (20’)

63. ADVANCES IN BREAST CANCER

ROOM D, 8.00-12.00 – Thursday, October 9

Chair Persons: J.E. Slansky, A.M. Cimpean, G. Broich

  • Analysis of the T-cell receptor repertoire in breast cancer using emusion single cell RT-PCR. D.J. Munson, T.C. Bruno, B.L. Moore, V.F. Borges, J.W. Kappler, J.E. Slansky (Aurora, CO; Portland, OR, USA) (30’)
  • Decreased expression and/or mutation of FRY, a promoter of epithelial cell differentiation, is associated with epithelial mesenchymal transition and clinical progression of breast cancer. H. Zarbl, N. Takizawa, J. Graham, B. Estrella, Z. Gong, X. Ren (Piscataway; North Brunswick, NJ; Buffalo, NY, USA) (30’)
  • Progress in the care for hereditary breast cancer: A twenty year anniversary. J. De Grève (Brussels, Belgium) (30’)
  • Social isolation stress induces obesity and unfolded protein response and autophagy in the mammary gland, and increases mammary tumorigenesis in mice. K. Cook, A. Sumis, E. Kidney, F. Andrade, R. Hu, X. Zhang, W. Yu, K.B. Bouker, R. Clarke, L. Hilakivi-Clarke (Washington, DC, USA; São Paulo, Brazil) (30’)
  • Canine mammary tumour: A spontaneous animal model for human breast cancer. B. Restucci (Naples, Italy)(30’)
  • Joint effects of genes, body constitution, and lifestyle: exploring novel pathways to predict prognosis and response to therapy in breast cancer. H. Jernström (Lund, Sweden) (30’)
  • Metabolomic profile of triple negative breast cancer in African American women reveals potential biomarkers of aggressive disease. Y.M. Kanaan, B.P. Sampey, D. Beyene, T.J. Naab, A.K. Esnakula, K.W. Blackman, L. Ricks-Santi, S. Dasi, Agnes Day, W. Frederick, R.L. Copeland, E. Gabrielson, R.L. DeWitty (Washington, DC, USA) (30’)

64. ADVANCES IN BREAST CANCER

ROOM D, 13.00-17.30 – Thursday, October 9

Chair Persons: L. Hilakivi-Clarke, M. Eskelinen

  • Breast brachytherapy fixation system: plastic tubes technique. L. Trigo, N. Stas (Porto, Portugal) (30’)
  • Vaccines for primary prevention of breast cancer. K.L. Knutson (Port St Lucie, FL, USA) (30’)
  • Targeted intraoperative radiation therapy – Advances In local therapy of breast cancer. W. Malter, V. Kirn, K. Rogee, L. Richters, P. Mallmann, S. Kraemer (Cologne, Germany) (20′)
  • Individual xenograft for women with metastatic triple negative breast carcinoma: a step toward personalized medicine. G. Bousquet, A. Janin (Paris, France) (20’)
  • Identify variant EPOR forms expressed in human breast cancers. Z. Rakosy, G. Paragh, G. Acs (Wauwatosa, WI; Tampa, FL, USA) (10’)
  • The potential benefit of scanned proton beam versus intensity modulated photon therapy as adjuvant radiation therapy in breast cancer. A. Dasu, A.M. Flejmer, F. Dohlmar, D. Josefsson, P. Witt Nyström (Linköping, Sweden) (15’)
  • Adult weight gain and breast density. C. Diorio (Quebec, QC, Canada; Carouge, Switzerland) (20’)

Chair Persons: A. Dasu, M. Raica

  • New aspects concerning the radiation of breast cancer. E. Bölke, C. Matuschek, W. Budach (Düsseldorf, Germany) (30’)
  • AAA vs PBC for treatment planning of breast cancer from the perspective of the National Swedish Breast Cancer Group recommendations. A.M. Flejmer, F. Dohlmar, M. Nilsson, M. Stenmarker, A. Dasu (Linköping, Sweden) (15’)
  • Evaluation of predictive markers for clinical outcome after neoadjuvant radiochemotherapy in breast cancer. C. Matuschek, H.B. Prisack, W. Audretsch, E. Bölke, C.N. Krämling, W. Budach, H. Bojar (Düsseldorf, Germany) (15’)

64P. ADVANCES IN BREAST CANCER (POSTERS)

  • Glycosylated oleic acid/vitamin D-binding protein suppresses HER2 oncogene expression in human breast cancer. M. Ruggiero, J.J.V. Branca, D. Noakes, M. Gulisano, G. Morucci, L. Thyer, S. Pacini (Firenze, Italy; Guernsey, Channel Islands, UK)
  • The relation of hopelessness and helplessness versus beck depression inventory (BDI) in healthy individuals and in patients with benign breast disease and breast cancer: a prospective case–control study in Finland. R. Korhonen, T. Selander, P. Ollonen and M. Eskelinen (Kuopio, Finland)
  • 15 years old girl with combination of juvenile papillomatosis, juvenile fibroadenoma and intraductal carcinoma of the breast. T. Sedloev, A. Bassarova, K. Angelov, M. Vasileva, Y. Asenov, K. Velikova (Oslo, Norway; Sofia, Bulgaria)
  • Levels of microvesicles isolated from blood of breast cancer patients is higher than in healthy women. O. Galindo Hernández, M.C. González Vázquez, C.V. Arellano Gutierrez, O.D. Reyes Hernández, M. Sierra Martínez and E. Pérez Salazar (México D.F., México)

65. NEW INSIGHTS IN BRAIN TUMORS
Special Symposium Organized by G. Sica and M. Jhanwar-Uniyal

ROOM E, 8.00-12.00  – Thursday, October 9

Chair Persons: G. Sica, M. Jhanwar-Uniyal

  • Genomic heterogeneity in glioblastoma: An overview of its clinical and therapeutic implications. S.C. Jhanwar (New York, NY, USA) (25’)
  • New strategies in the study of glioblastoma: A neurosurgical point of view. A. Mangiola, P. De Bonis, N. Saulnier, L. Lauriola, G. Lama, D. Orteschi, M. Zollino, M. Jhanwar-Uniyal, G. Maira, C. Anile, G. Sica (Rome, Italy) (25’)
  • Characterization of cancer stem cells derived from glioblastoma and peritumor tissue. G. Sica , G. Lama, A. Colabianchi, A. D’Alessio, G. Proietti, C. Angelucci, B.M. Scicchitano, A. Mangiola, E. Binda, A. Vescovi, G. Maira (Rome, Italy) (25’)
  • Glioblastoma multiforme: finding novel inhibitors for effective and selective targeting. J. L. Gillick, R. Murali, M. Jhanwar-Uniyal (Valhalla, NY) (25’)
  • Adult mouse sub-ventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling. N. Goffart, J. Kroonen, E. Di Valentin, M. Dedobbeleer, A. Denne, P. Martinive, B. Rogister (Liege, Belgium; Utrecht, The Netherlands) (20’)
  • An integrated view of the transcriptome and miRNome of glioblastoma and peritumor tissues. B. Fazi, D. Sicari, S. Galardi, M.G. Farace, G. Maira, P. De Bonis, C. Anile, A. Mangiola, S.A. Ciafré (Rome, Italy) (30’)

66. CANCER PREVENTION IN ASIA PACIFIC COUNTRIES
Special Symposium of the Asian Pacific Organization for Cancer Prevention (APOCP),
Organized by C.-H. Yip and C.-J. Chen

ROOM E, 13.00-16.00 – Thursday, October 9

Chair Persons: C.-J. Chen, C.-H. Yip

  • Cancer burden in the asia pacific region – trends and future challenges. J. Dunn (Brisbane, Australia) (25’)
  • Regional players in cancer control in Asia. M.A. Moore (Bangkok, Thailand) (30’)
  • National cancer screening program and improvement in cancer survival. in Korea. K.-Y. Yoo (Seoul, South Korea) (15’)
  • Prevention of breast cancer in Asia. C.H. Yip (Selangor, Malaysia) (30’)
  • Role of civil society organisations in cancer control. J. Dunn (Queensland, Australia) (25’)

67. TOXICOLOGY AND CANCER AETIOLOGY
Special Symposium of the Asian Pacific Organization for Cancer Prevention (APOCP),
Organized by C.-H. Yip and C.-J. Chen

ROOM E, 16.15-18.30 – Thursday, October 9

Chair Persons: C.-J. Chen, C.-H. Yip

  • Cancer prevention by control of infectious agents through immunization and therapy. C.J. Chen (Taipei, Taiwan) (30’)
  • Prevention strategy of adult t-cell leukemi/lymphoma by htlv-1 eradication. K. Tajima (Mie, Japan) (20’)
  • Ingested bovine lactoferrin promotes immune system responsiveness to inhibit carcinogenesis. D. B. Alexander, M. Iigo, H. Hamano, K. Yamauchi, J. Xu H. Tsuda, M.A. Moore (Bangkok, Thailand; Nagoya; Zama, Japan) (30’)
  • Epidemiology, screening and vaccination of HPV and cervical cancer in China. Y.L. Qiao (China) (20’)
  • Epidemiology of schistosomiasis and urinary bladder cancer in Egypt after the national schistosomiasis control programs. E. I. Salim (Tanta,Egypt) (15’)

68. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT
Special Symposium Organized by B. Littlefield

ROOM F, 08.00-12.00  – Thursday , October 9

Chair Persons: B. Littlefield, M. Hamann

  • Defining a new protein target for the selective treatment of melanoma. W. Fenical, L. Trzoss, J. LaClair, L.V. Costa-Lotufo, P. Jimenez (San Diego, CA, USA; Fortaleza, Brazil) (40′)
  • Screening natural product libraries for cancer-selective cytotoxins. D. Demers, M. Knestrick, C. Witowski, J. Von Salm, R. Green, L. Hamel, M. Howell, C. Powell, A. Ubaldani, L. Calcul, L. Chen, D. Mitchell, Y. Ren, B. Vesely, R. Deschenes, D.E. Kyle, S. Mohapatra, S. Westerheide, J. Wu, B.J. Baker (Tampa, FL, USA) (30′)
  • Inhibition of spontaneous and induced mutagenesis by natural compounds and mixtures. P.G. Sacks, Z.L. Zhao, W. Kosinska, Z. He, M. Khmelnitsky, J.H. Kim, J.B. Guttenplan (New York, NY, USA) (15′
  • The taccalonolides: plant derived microtubule stabilizers. S.L. Mooberry, A.L. Risinger, J. Peng, C.C. Rohena, J. Li, A.R.B. Ola, J. Kuhn (San Antonio, TX, USA) (40′)
  • Patemine A and congeners: Anticancer strategies with protein synthesis inhibitors. D. Romo (College Station, TX, USA) (40′)
  • Dietary constituents and experimental breast cancer. G. Vollmer, O. Zierau, B.M. Dietz, J.L. Bolton, G.F Pauli, D. Macejova (Dresden, Germany; Chicago, IL, USA; Bratislava, Slovak Republic) (15′)
  • A glimpse into natural product drug discovery at Eisai. M.H.D. Postema (Andover, MA, USA) (40′)

69. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT
Special Symposium Organized by B. Littlefield

ROOM F, 13.00-17.30 – Thursday , October 9

Chair Persons: S. Moobery, D. Romo

  • Taxol, tubulin and tumors. S.B. Horwitz (Bronx, NY, USA)(40’)
  • Discovery and development of anticancer lead compounds from marine Cyanobacteria. W. Gerwick (La Jolla, CA, USA) (30′)
  • Chemical and biological syntheses of polyketide regulators of proteostasis. R.E. Taylor (Notre Dame, IN, USA) (40′)
  • EGFR inhibition by curcumin in cancer cells: a dual mode of action. M. Starok, P. Preira, M. Vayssade, K. Haupt, L. Salomé, C. Rossi (Compiègne; Toulouse, France) (10′)
  • Structural specificity of genin flavonoids suppresses the commotion of aromatase and cathepsin D, pivotal targets for breast cancer. S. Luqman, V. Dubey, N. Masood (Lucknow, India) (10′)
  • Chemistry and biology of the marine natural product psymberin. J.K. De Brabander (Dallas, TX, USA) (40′)
  • Studies of anti-cancer activities of naturally occurring terpene extracted from the seeds of Pithcellobium dulce plant. S.H. Ganatra, A. Ramteke (Nagpur, India)

69P. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT (POSTERS)

  • Antitumor potential of the low-molecular fucoidan proven on several in vivo models. M.Y. Khotimchenko, E.P. Zueva, R.Y. Khotimchenko, T.G. Razina, V.V. Kovalev (Vladivostok; Tomsk, Russia)
  • Modified pectin compounds exert different effects on Ehrlich ascites tumor cells and Lewis lung carcinoma in mice. Y.S. Khotimchenko, N.V. Shilova, K.A. Lopatina, M.Y. Khotimchenko, E.P. Zueva (Vladivostok; Tomsk, Russia)
  • In vitro and in vivo anti-cancer effect of C. striatus mushroom extract on human pancreatic cancer cells. L.E. Sharvit, S.P. Wasser, F. Fares (Haifa, Israel; Kiev, Ukraine)
  • Antiproliferative and differentiation-promoting effects of ethanol-water extracts of Kazakhstan medicinal plants on human acute myeloid leukemia cells. G.T. Zhamanbayeva, M. K. Murzakhmetova, S. T. Tuleukhanov, M. Danilenko (Almaty, Kazakhstan; Beer Sheva, Israel)
  • A novel anticancer alkaloid tiliacorinine induces sustained activation of the extracellular signal-regulated kinase and synergizes with cisplatin in cholangiocarcinoma cells. S. Janeklang, W. Seubwai, K. Vaeteewoottacharn, P. Boonsiri, G. Kismali, A. Nakaew, A. Suksamrarn, S. Okada, S. Wongkham (Khon Haen; Bangkok, Thailand; Ankara, Turkey; Kumamoto, Japan)
  • Potential anticancer activity of oregano essential oil extracted from Origanum vulgare SSP. Hirtum with its major constituent carvacrol against experimental colon cancer. A. Tiptiri-Kourpeti, K. Spyridopoulou, E. Fitsiou, G. Aindelis, S. Vasileiadis, G. Saxami, E. Nakou, D. Tsimogiannis, V. Oreopoulou, A. Galanis, A. Pappa, K. Chlichlia (Alexandroupolis; Athens, Greece)
  • Bambusa textilis: Comparison between methanolic and ethyl acetate extracts over the Ehrlich ascites tumor growing and the production of Nitric Oxide – NO. A.C.C. Trizolio, F.A.T. Neves, M.F. Bellini, D.H. Constantino (Bauru, SP, Brazil)
  • Targeting cancer pathway kinases with phytochemicals: an in silico study. A.A. Alhaddad, R. Vijayan (Al Ain, Abu Dhabi, United Arab Emirates)
  • A comparative – in vitro study cytotoxicity of Ocimum sanctum and Nepeta cataria volatile oils. F.M. Ibrahim, M.E. Ibrahim, S.F. El Habbasha (Cairo, Egypt)
  • Extracts from Tanacetum vulgare l. and Cotinus coggygria scop. exert a lower in vitro inhibitory effect on normal mammary epithelial cell viability than on breast cancer. Z. Gospodinova, G. Antov, R. Christova, M. Krasteva (Sofia, Bulgaria)
  • Antiproliferative effect of homobrassinin in human cancer cells. M. Kello, D. Drutovic, M. Chripkova, M. Pilatova, M. Budovska, L. Kulikova, L. Mirossay, G. Mojzisova, J. Mojzis (Kosice, Slovak Republic)

Friday, October 10


70. INVASION AND METASTASIS

ROOM A, 08.00-12.00 – Friday, October 10

Chair Persons: Y.G. Man, K. Nakamura

  • A novel hypothesis for tumor invasion and metastasis. Y.G. Man, I. Avital, A. Stojadinovic (Richmond, VA, USA) (30’)
  • Effects of inflammatory stimulation on programmed cell death 4 expression and invasive activity in human colorectal carcinoma cells. K. Nakamura, S. Sasaki, M. Hatai, S. Kagota, K. Shinozuka, N. Yoshikawa (Nishinomiya, Hyogo, Japan) (15’)
  • WAP-T mice: A preclinical mouse model to study mammary carcinogenesis, progression, and metastasis. F. Wegwitz, E. Lenfert, C. Mänz, G. Tolstonog, W. Deppert (Hamburg; Göttingen, Germany; Lausanne, Switzerland) (30’)
  • Pathobiological pathways with clinical significance involved in hepatic metastases from colorectal cancer -recent advances. K.A. Paschos, A.W. Majeed, N.C. Bird (Sheffield, UK) (20’)
  • A choelsterol lowering drug prevents osteolyitc bone metastasis by targeting osteoclastogenic factors in bone microenvironment. C.C. Mandal (Ajmer, Rajasthan, India) (15’)
  • The progression of breast cancer is associated with decrease of level of new ARP2/3 inhibitor arpin. M.E. Lomakina, R. Gorelik, I. Dang, V.D. Ermilova, A. Gautreau, A.Y. Alexandrova (Moscow, Russia; Gif-sur-Yvette, France) (20’)
  • Genetic factors involved in human colorectal cancer metastasis. O. Bajenova, S.J. O’Brien (St. Petersburg, Russia) (20’)

71. INVASION AND METASTASIS

ROOM A, 13.00-16.00 Friday, October 10

Chair Persons: A.Z. Dudek, M. Schauer

  • Transcription factor FoxM1 and tumor suppressor ARF effect on melanoma tumor angiogenesis and metastases. A.Z. Dudek, K. Terai (Chicago, IL, USA) (30’)
  • Heparin attenuates melanoma metastasis by interference with binding and signaling function of the integrin VLA-4. M. Schlesinger, U. Gerber, P. Schmitz, L. Borsig, G. Bendas (Bonn, Germany; Zurich, Switzerland) (30’)
  • Increased circulation of galectin-3 in cancer patients is an important metastasis promoter and attractive therapeutic target. L-G Yu (Liverpool, UK) (30’)
  • Genome-wide analysis targeting focal adhesion signaling in metastatic breast cancer and early translation for therapeutic applications. M.A. Alaoui-Jamali (Montreal, QC, Canada) (30’)
  • Bone metastases in renal cell carcinoma are promoted by Calcium via calcium sensing receptor signaling. W. Brenner, E.Jöckel, T. Haber, F.C. Roos, D. Prawitt, K. Junker, C. Hampel, J.W. Thüroff (Mainz; Hombur/Saar, Germany) (15’)
  • In vitro modelling of colorectal cancer cell arrest in the hepatic sinusoids: cancer cell interactions with kupffer cells and sinusoidal endothelial cells in colorectal cancer liver metastasis. K.A. Paschos, A.W. Majeed, N.C. Bird (Sheffield, UK) (15’)

71P. INVASION AND METASTASIS (POSTERS)

  • A biohybrid microfluidic system for an in vitro analysis of tumor metastases through blood vessels. S. Hensler, S. Kayo, C. Kuehlbach, J. Sechi, H. Hoefemann,S. Herrlich, R. Zengerle, M. Mueller (Villingen-Schwenningen, Germany)
  • The tensin intracellular protein family – functional roles of the individual protein domains. S. Hafizi (Portsmouth, UK)
  • A role for NEDD9 in tumor cell invasion. M. Semelakova, S.E. Grauzam, J.A. Tiedeken, S.A. Rosenzweig (Charleston, SC, USA; Košice, Slovakia)
  • Relationship among EGF, EGFR and PRL-3 expression in gastric cancer. A. Pryczynicz, M. Gryko, K. Niewiarowska, A. Kemona, K. Guzinska-Ustymowicz (Bialystok, Poland)

72. ADVANCES IN GYNECOLOGICAL CANCER

ROOM B, 8.00-12.00 – Friday, October 10

Chair Persons: R. Ganapathi, D. Kieback

  • Gene expression profiling of ovarian cancer: Are we making progress? R. Ganapathi, J. Sehouli, I. E. Braicu and M. Ganapathi (Charlotte, NC, USA; Berlin, Germany) (15’)
  • Next generation expression profiling of primary and recurrent ovarian tumors. M. K. Ganapathi, W. Jones, J. Sehouli, C. M. Michener, I. E. Braicu, C. Biscotti, S. A.J. Vaziri and R. N. Ganapathi (Charlotte; Durham, NC; Cleveland, OH, USA; Berlin, Germany) (15’)
  • The main principles of treatment for the early stage borderline ovarian tumors in women of reproductive age. I.N. Pinchuk , M.A. Liushnenko (Surgut, Russia) (10’)
  • Could HE4 help in decision-making in relation to the individualization of the extent of surgical staging in patients with endometrial cancer. J. Presl, Z. Novotny, O. Topolcan, P. Vlasak, R. Kucera, R. Fuchsova, J. Vrzalova and L. Betincova (Pilen, Czech Republic) (15’)
  • Breast cancer risk prediction: A journey from accurate information on breast cancer diagnosis, to epidemiology and biomarkers. E.O. Fourkala (London, UK) (20’)
  • Modeling for a comprehensive tissue-based repository supporting translational discoveries in ovarian cancer. D. Bassiouny, M. Naeim, S. Nofech-Mozes, N. Ismiil, V. Dubé, G. Han, M. Cesari, E. Slodkowska, F-I. Lu, S. Salama, H.F.Chiu, M.A. Khalifa (Toronto, ON, Canada) (15’)
  • Microcirculation in patients with gynecological cancer. I. Tikhomirova, D. Lileev, N. Kislov, I. Gordeev, M. Schekaleva (Yaroslavl, Russia) (10’)
  • E-cadherin -160 C/A genetic polymorphism and cervical intraepithelial neoplasia. I.C. Rotar, D. Mursan, F. Petrisor, P. Radu, P. Cotutiu, F. Stamatian (Cluj Napoca, Romania) (15′)
  • Borderline ovarian tumors – are they benign or malignant? A. Lazarou, C. Fotopoulou, A. Coumbos, J. Sehouli, J. Vasiljeva, I. Braicu, H. Burger, W. Kuehn (Berlin, Germany) (20’)

72P. ADVANCES IN GYNECOLOGICAL CANCER (POSTERS)

  • Correlation of PKM2 expression with clinicopathological data in ovarian cancer. C. Kobierzycki, K. Jablonska, T. Wysocka, M. Zabel, E. Nowak-Markwitz, M. Spaczynski, M. Podhorska-Okolow, P. Dziegiel (Wroclaw; Poznan, Poland)
  • CLASP1 gene expression in ovarian cancer is related with survival. K.M. Lisowska, M. Olbryt, S. Student, K. Kujawa, A.J. Cortez,I.K. Rzepecka, J. Kupryjanczyk (Gliwice; Warsaw, Poland)
  • Nocturnal activity through adipokines, in correlation with endometrial cancer. R. Ciortea, N. Costin, A. Malutan, C. Bucuri, L. Angheluta, D. Mihu (Cluj-Napoca, Romania)
  • Long term follow-up of borderline ovarian tumors. A. Lazarou, C. Fotopoulou, A. Coumbos, J. Sehouli, J. Vasiljeva, I. Braicu, H. Burger, W. Kuehn (Berlin, Germany)

73. ADVANCES IN HEAD AND NECK CANCER

ROOM B, 13.00-15.30 – Friday, October 10

Chair Person: S. Syrjänen, K. Syrjänen

  • Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab. N. Murakami, S. Yoshimoto, F. Matsumoto, T. Ueno, Y. Ito, K. Kobayashi, K. Harada, M. Kitaguchi, S. Sekii, K. Takahashi, K. Yoshio, K. Inaba, M. Morota, M. Sumi, Y. Saito, J. Itami (Tokyo, Japan) (15’)
  • Natural history of HPV in head and neck region- where are we now? S. Syrjänen (Turku, Finland) (40’)
  • Potentiation of cetuximab by inhibition of tregs in metastatic squamous cell cancers of head and neck. G.L. Jha, J.S. Miller (Minneapolis, MN, USA) (20’)
  • Runx genes – promising biomarkers for metastatic spread in oropharyngeal carcinomas. P. Papagerakis, Y. Seon, L. Zheng, M.A. Sartor, Y. Zhang, E. Bellile, B. Li, M. Matossian, M. Pliakas, O. Shkeir, J. McHugh, G. Pannone, D. Chepeha, G. Wolf, C. Ge, R.T. Franceschi, S. Papagerakis (Ann Arbor, MI, USA; Foggia, Italy) (30’)
  • Clinical Significance of Kallikrein-related-peptidase-4 in Oral Cancer. P. Papagerakis, G. Pannone, M. Athanassiou-Papaefthymiou, Y. Yamakoshi, S. McGuff, O. Shkeir, K. Ghirtis, S. Papagerakis (Ann Arbor, MI; San Antonio, TX, USA; Foggia, Italy) (20’)

73P. ADVANCES IN HEAD AND NECK CANCER (POSTER)

  • Protein and mRNA expression of Notch pathway components in operable tumors of laryngeal cancer patients. D. Krikelis, V. Kotoula, M. Bobos, E. Fountzilas, K. Markou, I. Karasmanis, N. Angouridakis, K. Vlachtsis, K.T. Kalogeras, A. Nikolaou, G. Fountzilas (Thessaloniki; Athens, Greece)

74. TUMOR ANGIOGENESIS AND ANTI- ANGIOGENESIS

ROOM C, 08.00-12.00 – Friday, October 10

Chair Persons: S. Kumar, W.G. Jiang, G. Sica

  • Anti-angiogenesis: targeting cd105 in cancer patients-what next? W.H. Fang, P. Kumar, S. Kumar (Manchester, UK) (20′)
  • Glioblastoma cancer stem cells and angiogenesis. A. Colabianchi, G. Lama, A. D’Alessio, G. Proietti, C. Angelucci, A. Mangiola, G. Maira, E. Binda, A. Vescovi, G. Sica (Rome; Milan, Italy) (15′)
  • New and alternative approaches in targeting angiogenesis and metastasis. W.G. Jiang (Cardiff, UK) (30′)
  • mTOR/PI3k/Akt signaling pathway in tumor angiogenesis and therapeutic targeting. P. Mabeta, P.F. Davis, M.S. Pepper (Thswane, South Africa; Wellington, New Zealand) (15′)
  • Expression of angiogenesis-related factors in glioblastoma and peritumor tissue. G. Lama, A. Colabianchi, G. Proietti, A. Mangiola, F. Biamonte, G. Maira, G. Sica (Rome, Italy) (15′)
  • Regulation of angiogenesis by WNT signalling in non-small cell lung cancers. V. Sarosi, J. Rapp, T. Kovacs, D. Feller, G. Smuk, J.E. Pongracz (Pecs, Hungary) (30′)
  • Three dimensional in vitro models for studying cancer angiogenesis. L. Bray (Dresden, Germany) (10′)
  • Effects of a mast cell stabilizer on the vascularization of mammary tumors: Ultrasonographic evaluation. A.I.Faustino-Rocha, A. Gama, M.J. Pires, P.A. Oliveira, M. Ginja (Vila Real, Portugal) (15′)

74P. TUMOR ANGIOGENESIS AND ANTI- ANGIOGENESIS (POSTERS)

  • MicroRNA-320 is an anti-angiogenic factor by targeting neuropilin. T.M. Hong, Y.Y. Wu, Y.C. Jao, Y.L. Chen (Tainan, Taiwan)
  • Galectin-1 plays a pivotal role in the regulation of tumor vasculature. Y.-L. Chen, M.-H. Wu, N.-W. Ying, T.-M. Hong (Tainan, Taiwan)
  • Endothelial cell proliferation and vascular endothelial growth factor expression in primary colorectal cancer compared with corresponding liver metastases. A.R. Ceausu, A.M. Cimpean, O. Cretu, O. Mederle, A. Ciolofan, P. Gaje, M. Raica (Timisoara, Romania)
  • EGFR+/D2-40+/E-Cadherin+: A potential phenotype for agressiveness in head and neck squamous cell carcinoma. R.A. Ceausu, N.C. Balica, A.M. Cimpean, P.N. Gaje, H. Stefanescu, M. Poenaru, C. Doros, M. Raica (Timisoara, Romania)
  • Evaluation of two kinase inhibitors on melanoma cell lines in cam assay. P.N. Gaje, S. Avram, I. Krizbai, I. Wilhelm, A.M. Cimpean, A.R. Ceausu, M. Raica (Timisoara, Romania; Szeged, Hungary)
  • The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in rat colorectal cancer model. H. Gungor, N. Ilhan, N. Ilhan (Elazig, Turkey)

75. MELANOMA: NEW THERAPIES AND BIOMARKERS

ROOM C, 13.00-15.30 – Friday, October 10

Chair Persons: F.J. Lejeune, O. Zoras

  • New Achilles heels in melanoma? F.J. Lejeune (Lausanne, Switzerland) (20′)
  • Isolated limb perfusion with TNFa and melfalan for unresectable melanoma and soft tissue sarcoma. O. Zoras (Heraclion, Greece) (30’)
  • Prognostic value of perioperative assessment of circulating melanoma cells in hyperthermic isolated limb perfusion: interim results. D. Michelakis, I. Messaritakis, K. Lasithiotakis, H. Ioannou, I. Souglakos, D. Stamatiou, O. Zoras (Heraklion, Greece; York, UK) (10′)
  • Comparative metabolomics of primary and metastatic melanoma cells – towards novel diagnostic method. G.K. Ramachandran (Singapore, Singapore) (15′)

75P. MELANOMA: NEW THERAPIES AND BIOMARKERS (POSTERS)

  • Platelet-derived endothelial cell growth factor expression in cutaneous malignant melanomas. S. Yilmazer, F.K. Dagistanli, G. Kaner (Istanbul, Turkey)
  • Anti-melanoma activity of WP760 in various in vitro culturing conditions. M. Olbryt, A. Rusin, I. Fokt, A. Habryka, A. Sochanik, W. Priebe, (Gliwice, Poland; Houston, TX, USA)
  • Epidemiological profile of cutaneous melanoma in Morocco. W. Mahfoud, H. Amrani Hassani Joutei, I. Saadaoui, N. Elgnaoui, H. Lebrazi, H. Benomar (Casablanca, Morocco)
  • Personalized synthetic lethality induced by targeting RAD52 and PARP1 in melanomas. M. Toma, A. Gajos-Michniewicz, K. Majchrzak, L. Wieteska, J. Szemraj, M. Czyz, T.Skorski, T. Sliwinski (Lodz, Poland; Philadelphia, PA, USA)

76. ADVANCES IN BREAST CANCER

ROOM D, 08.00-12.00 – Friday, October 10

Chair Persons: P.A. Townsend, S. Kraemer

  • Annexin A3 is a breast cancer marker secreted by neoplastic cell lines and involved in cell migration. B.A. Zeidan, T. Jackson, S.E.T. Larkin, R.I. Cutress, G.R. Coulton, M. Ashton-Key, N. Murray, H.E. Johnston, G. Packham, S.D. Garbis, P.A. Townsend (Southampton; London; Manchester, UK) (30′)
  • Local breast cancer treatment with targeted oncoplastic breast surgery. S. Kraemer, W. Malter, V. Kirn, K. Rogee, L. Richters, P. Mallmann (Cologne, Germany) (20′)
  • New strategies to overcome endocrine resistance in metastatic breast cancer. S. Kraemer, M. Wirtz, V. Kirn, L. Richters, J. Puppe, A. Ulhaas, K. Rogee, W. Malter, P. Mallmann (Cologne, Germany) (20′)
  • Primary breast cancer and corresponding axilary lymph node metastases: do they have the same molecular profile? M. Raica (Timisoara, Romania) (30′)
  • Estrogen blockade and tailored chemotherapy in high risk premenopausal breast cancer (BC). F. Recchia, S. Necozione, M. Bratta, S. Rea (Avezzano; Rome; L’Aquila, Italy) (15′)
  • Lymphangiogenesis in molecular types of breast cancer. A.M. Cimpean, M. Raica (Timisoara, Romania) (20′)
  • Polymorphisms in CYP19A1 gene predicts relapse and survival in postmenopausal breast cancer patients treated with adjuvant letrozole. G. Umamaheswaran, D. Kadambari, B. Dubashi, K.R. Reddy, C. Adithan, S.A. Dkhar (Pondicherry, India) (15′)

77. ADVANCES IN HEMATO-ONCOLOGY

ROOM D, 13.00-16.00 – Friday, October 10

Chair Persons: A. Polliack, V. Barak, T. Tadmor

  • Recent advances in management of CML. B. Shah (Lewiston, ID, USA) (30′)
  • Thymidine Kinase (TK) levels can discriminate patients with a Low to High Grade Lymphoma transformation. V. Barak, N. Goldschmidt, I. Kalichman, M.E. Gatt (Jerusalem, Israel) (30′)
  • Richter syndrome in chronic lymphocytic leukemia: A retrospective study reporting clinical data and outcome from the Israeli CLL Study Group. T. Tadmor, L. Shvidel, O. Bairey, N. Goldschmidt, R. Ruchlemer, R. Fineman, N. Rahimi-Levene, Y. Herishanu, M. Yuklea, A. Arad, A. Aviv, A. Polliack (Tel Aviv; Jerusalem; Haifa; Kfar Saba; Natanya, Israel) (30′)
  • Therapeutic potential of targeting sphingosine kinases in T-cell acute lymphoblastic leukemia. C. Evangelisti (Bologna, Italy) (30′)

77P. ADVANCES IN HEMATO-ONCOLOGY (POSTERS)

  • Canine as an animal model of P-glycoprotein expression in lymphoma cells. J. Sokolowska, K. Urbanska, S. Gizinski, R. Lechowski (Warsaw, Poland)
  • Canine as an animal model of survivin expression in lymphoma cells. J. Sokolowska, K. Urbanska, S. Gizinski, R. Lechowski (Warsaw, Poland)
  • Cytomegalovirus infection in hematological patients following autologous peripheral stem cell transplantation. K. Piukovics, G. Terhes, J. Deák, Z. Borbényi (Szeged, Hungary)

78. MICRORNAS IN CANCER

ROOM E, 09.00-11.00 – Friday, October 10

Chair Persons: F. Pentimalli, A. Seth

  • Targeting malignant mesothelioma: multiple approaches are required. F. Pentimalli, L. Esposito, I.M. Forte, D. Di Marzo, C.A. Iannuzzi, P. Indovina, A. Giordano (Naples; Siena, Italy; Philadelphia, PA, USA) (30’)
  • Aberrant miR-182 expression enhances the metastatic potential of prostate cancer and is associated with clinical recurrence. A. Gordanpour, Y. Amemiya, R. Nam, J. Bendavid, L. Sugar, A. Seth (Toronto,ON, Canada) (15’)
  • Epigenetics and regulatory microRNAs in the development and control of tumor. K.P. Gupta, P. Tiwari (Lucknow, India) (30’)
  • MiRNA expression profiling of locally advanced breast cancer (LABC) during neo-adjuvant chemotherapy (NAC) M. Al-Khanbashi, S. Caramuta, A. Al-Ajmi, I. Al-Haddabi, L.Weng-Onn, M. Al-Moundhri (Solna, Sweden) (10’)

78P. MICRORNAS IN CANCER (POSTERS)

  • Regulation of BRCA1 expression by miRNAs in breast cancer cell lines. I. Fkih M’Hamed, M. Privat, F. Penault-Llorca, A. Kenani, Y.J. Bignon (Clermont-Ferrand, France; Monastir, Tunisia)
  • Profile of microRNAs in gastric cancer tissues and normal gastric mucosa. V. Salteniene, J. Kupcinskas, R. Ramonaite, S. Juzenas, A. Link, G. Kiudelis, L. Jonaitis, J. Skieceviciene, S. Jarmalaite, L. Kupcinskas, P. Malfertheiner(Kaunas; Vilnius, Lithuania; Magdeburg, Germany)
  • Simultaneous analysis of the expression of splicing factors and mirtrons in digestive system tumours and cell lines. G. Vilkaitis, S. Butkyte, E. Jakubauskiene, A. Scerbakovaite, A. Kanopka(Vilnius, Lithuania)
  • Expression correlations of NFkBsignaling and miR146 a/b miR21 and let-7 expression in primary human head and neck squamous cell carcinomas. G. Pajkos, I. Sejben, K. Gombos, I. Kiss, S.Z. Baán, R. Horváth, L. Olasz (Kecskemet; Pecs, Hungary)
  • The role of mRNA expression profiles in head and neck cancer tissue organization field detection. K. Gombos, E. Orosz, R. Horváth, I. Szanyi, K. Somlai,L. Olasz (Pecs; Veszprem, Hungary)
  • Redsludge-induced mRNA and miRNA expression alterationstested in CBA/Ca mice. A. Tibold, J. Krisztina, G. Katalin, G. Katalin, I. Kiss (Pécs, Hungary)
  • MicroRNA expressions in HPV induced cervical dysplasia and cancer. K. Gocze, K. Kovacs, P. Gocze, I. Kiss (Pécs, Hungary)

79. NATURAL PRODUCTS IN CANCER DRUG DEVELOPMENT
Special Symposium Organized by B.A. Littlefield

ROOM F, 09.00-12.30 – Friday, October 10

Chair Persons: M. Postema, J. De Brabander

  • Development of eribulin, a macrocyclic ketone analog of halichondrin B, for advanced breast cancer. B.A. Littlefield (Andover, MA, USA) (40′)
  • Karlotoxins exhibit a unique mechanism for the control of cancer cells. M.T. Hamann (Oxford, MS, USA) (20′)
  • Antiproliferative and proapoptotic actions of highly purified betanin extracted from Beta vulgaris on MCF-7 cancer cells. L. Nowacki, P. Vigneron, F. Merlier, L. Rotellini, R. Ralanairina, J.-P. Gadonna, C. Rossi, M. Vayssade (Compiègne; Beauvais, France) (15′)
  • Cancer drug discovery from fragments to marine natural products. R. Li (Omaha, NE, USA) (25′)
  • Anticancer drug discovery based on plant biodiversity. H. Zhang, K. Liu, Y.Guan (Kowloon, Hong Kong) (10′)
  • Essential oil extracted from the resin of Pistacia lentiscus var chia (mastic oil): Antitumor efficacy against colorectal cancer. K. Spyridopoulou, A. Tiptiri-Kourpeti, E. Fitsiou, S. Vaseiliadis, H. Bardouki, A. Galanis, A. Pappa, K. Chlichlia (Alexandroupolis; Athens, Greece) (10′)